Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Neoplasms of the CNS

  Free Subscription


Articles published in J Neurooncol

Retrieve available abstracts of 521 articles:
HTML format
Text format



Single Articles


    May 2017
  1. GLASER SM, Dohopolski MJ, Balasubramani GK, Flickinger JC, et al
    Glioblastoma multiforme (GBM) in the elderly: initial treatment strategy and overall survival.
    J Neurooncol. 2017 May 19. doi: 10.1007/s11060-017-2493.
    PubMed     Text format     Abstract available


  2. VOSS KM, Spille DC, Sauerland C, Molina ES, et al
    The Simpson grading in meningioma surgery: does the tumor location influence the prognostic value?
    J Neurooncol. 2017 May 19. doi: 10.1007/s11060-017-2481.
    PubMed     Text format     Abstract available


  3. DIAZ RJ, Ali S, Qadir MG, De La Fuente MI, et al
    The role of bevacizumab in the treatment of glioblastoma.
    J Neurooncol. 2017 May 19. doi: 10.1007/s11060-017-2477.
    PubMed     Text format     Abstract available


  4. RENOVANZ M, Hechtner M, Janko M, Kohlmann K, et al
    Factors associated with supportive care needs in glioma patients in the neuro-oncological outpatient setting.
    J Neurooncol. 2017 May 19. doi: 10.1007/s11060-017-2484.
    PubMed     Text format     Abstract available


  5. ESEONU CI, Eguia F, ReFaey K, Garcia O, et al
    Comparative volumetric analysis of the extent of resection of molecularly and histologically distinct low grade gliomas and its role on survival.
    J Neurooncol. 2017 May 19. doi: 10.1007/s11060-017-2486.
    PubMed     Text format     Abstract available


  6. YUAN G, Niu L, Zhang Y, Wang X, et al
    Defining optimal cutoff value of MGMT promoter methylation by ROC analysis for clinical setting in glioblastoma patients.
    J Neurooncol. 2017 May 17. doi: 10.1007/s11060-017-2433.
    PubMed     Text format     Abstract available


  7. WION D
    Therapeutic dormancy to delay postsurgical glioma recurrence: the past, present and promise of focal hypothermia.
    J Neurooncol. 2017 May 17. doi: 10.1007/s11060-017-2471.
    PubMed     Text format     Abstract available


  8. KUMTHEKAR P, Grimm S, Chandler J, Mehta M, et al
    A phase II trial of arsenic trioxide and temozolomide in combination with radiation therapy for patients with malignant gliomas.
    J Neurooncol. 2017 May 16. doi: 10.1007/s11060-017-2469.
    PubMed     Text format     Abstract available


  9. STORY E, Johnston DL, Bartels U, Carret AS, et al
    Embryonal tumors in Canadian children less than 36 months of age: results from the Canadian Pediatric Brain Tumor Consortium (CPBTC).
    J Neurooncol. 2017 May 16. doi: 10.1007/s11060-017-2468.
    PubMed     Text format     Abstract available


  10. JIN C, Li M, Ouyang Y, Tan Z, et al
    MiR-424 functions as a tumor suppressor in glioma cells and is down-regulated by DNA methylation.
    J Neurooncol. 2017 May 15. doi: 10.1007/s11060-017-2438.
    PubMed     Text format     Abstract available


  11. GESSLER F, Baumgarten P, Bernstock JD, Harter P, et al
    Assessment of molecular markers demonstrates concordance between samples acquired via stereotactic biopsy and open craniotomy in both anaplastic astrocytomas and glioblastomas.
    J Neurooncol. 2017 May 15. doi: 10.1007/s11060-017-2448.
    PubMed     Text format     Abstract available


  12. CHEN Y, Li R, Pan M, Shi Z, et al
    MiR-181b modulates chemosensitivity of glioblastoma multiforme cells to temozolomide by targeting the epidermal growth factor receptor.
    J Neurooncol. 2017 May 13. doi: 10.1007/s11060-017-2463.
    PubMed     Text format     Abstract available


  13. FONTANA AO, Piffaretti D, Marchi F, Burgio F, et al
    Epithelial growth factor receptor expression influences 5-ALA induced glioblastoma fluorescence.
    J Neurooncol. 2017 May 12. doi: 10.1007/s11060-017-2474.
    PubMed     Text format     Abstract available


  14. MALGULWAR PB, Nambirajan A, Pathak P, Faruq M, et al
    Study of beta-catenin and BRAF alterations in adamantinomatous and papillary craniopharyngiomas: mutation analysis with immunohistochemical correlation in 54 cases.
    J Neurooncol. 2017 May 12. doi: 10.1007/s11060-017-2465.
    PubMed     Text format     Abstract available


  15. CHAMBERLAIN MC, Kim BT
    Nivolumab for patients with recurrent glioblastoma progressing on bevacizumab: a retrospective case series.
    J Neurooncol. 2017 May 12. doi: 10.1007/s11060-017-2466.
    PubMed     Text format     Abstract available


  16. BALENDRAN S, Liebmann-Reindl S, Berghoff AS, Reischer T, et al
    Next-Generation Sequencing-based genomic profiling of brain metastases of primary ovarian cancer identifies high number of BRCA-mutations.
    J Neurooncol. 2017 May 11. doi: 10.1007/s11060-017-2459.
    PubMed     Text format     Abstract available


  17. VECHT C, Duran-Pena A, Houillier C, Durand T, et al
    Seizure response to perampanel in drug-resistant epilepsy with gliomas: early observations.
    J Neurooncol. 2017 May 10. doi: 10.1007/s11060-017-2473.
    PubMed     Text format     Abstract available


  18. ARNESON K, Mondschein J, Stavas M, Cmelak AJ, et al
    A phase I trial of concurrent sorafenib and stereotactic radiosurgery for patients with brain metastases.
    J Neurooncol. 2017 May 9. doi: 10.1007/s11060-017-2455.
    PubMed     Text format     Abstract available


  19. QIAO W, Zhao L, Wu S, Liu C, et al
    SPECT imaging and radionuclide therapy of glioma using 131I labeled Buthus martensii Karsch chlorotoxin.
    J Neurooncol. 2017 May 9. doi: 10.1007/s11060-017-2456.
    PubMed     Text format     Abstract available


  20. MAZUROWSKI MA, Clark K, Czarnek NM, Shamsesfandabadi P, et al
    Radiogenomics of lower-grade glioma: algorithmically-assessed tumor shape is associated with tumor genomic subtypes and patient outcomes in a multi-institutional study with The Cancer Genome Atlas data.
    J Neurooncol. 2017 May 3. doi: 10.1007/s11060-017-2420.
    PubMed     Text format     Abstract available


  21. AHMED KA, Kim S, Arrington J, Naghavi AO, et al
    Outcomes targeting the PD-1/PD-L1 axis in conjunction with stereotactic radiation for patients with non-small cell lung cancer brain metastases.
    J Neurooncol. 2017 May 2. doi: 10.1007/s11060-017-2437.
    PubMed     Text format     Abstract available


    April 2017
  22. SCRIBNER E, Hackney JR, Machemehl HC, Afiouni R, et al
    Key rates for the grades and transformation ability of glioma: model simulations and clinical cases.
    J Neurooncol. 2017 Apr 27. doi: 10.1007/s11060-017-2444.
    PubMed     Text format     Abstract available


  23. MIYAZAKI T, Ishikawa E, Matsuda M, Akutsu H, et al
    Assessment of PD-1 positive cells on initial and secondary resected tumor specimens of newly diagnosed glioblastoma and its implications on patient outcome.
    J Neurooncol. 2017 Apr 26. doi: 10.1007/s11060-017-2451.
    PubMed     Text format     Abstract available


  24. HAN H, Han C, Wu X, Zhong S, et al
    Preoperative grading of supratentorial nonenhancing gliomas by high b-value diffusion-weighted 3 T magnetic resonance imaging.
    J Neurooncol. 2017 Apr 24. doi: 10.1007/s11060-017-2423.
    PubMed     Text format     Abstract available


  25. DARLIX A, Deverdun J, Menjot de Champfleur N, Castan F, et al
    IDH mutation and 1p19q codeletion distinguish two radiological patterns of diffuse low-grade gliomas.
    J Neurooncol. 2017 Apr 22. doi: 10.1007/s11060-017-2421.
    PubMed     Text format     Abstract available


  26. YANO H, Nakayama N, Ohe N, Miwa K, et al
    Pathological analysis of the surgical margins of resected glioblastomas excised using photodynamic visualization with both 5-aminolevulinic acid and fluorescein sodium.
    J Neurooncol. 2017 Apr 21. doi: 10.1007/s11060-017-2445.
    PubMed     Text format     Abstract available


  27. EMERY IF, Gopalan A, Wood S, Chow KH, et al
    Expression and function of ABCG2 and XIAP in glioblastomas.
    J Neurooncol. 2017 Apr 21. doi: 10.1007/s11060-017-2422.
    PubMed     Text format     Abstract available


  28. HAQUE W, Verma V, Butler EB, Teh BS, et al
    Patterns of care and outcomes of multi-agent versus single-agent chemotherapy as part of multimodal management of low grade glioma.
    J Neurooncol. 2017 Apr 21. doi: 10.1007/s11060-017-2443.
    PubMed     Text format     Abstract available


  29. YOULAND RS, Schomas DA, Brown PD, Parney IF, et al
    Patterns of care and treatment outcomes in older adults with low grade glioma: a 50-year experience.
    J Neurooncol. 2017 Apr 21. doi: 10.1007/s11060-017-2439.
    PubMed     Text format     Abstract available


  30. WU L, Yang C, Liu T, Fang J, et al
    Clinical features and long-term outcomes of pediatric spinal meningiomas.
    J Neurooncol. 2017 Apr 21. doi: 10.1007/s11060-017-2441.
    PubMed     Text format     Abstract available


  31. BUGLIONE M, Triggiani L, Magrini SM
    The growing role of biology in the treatment of glioblastoma: no more one kind of disease.
    J Neurooncol. 2017 Apr 20. doi: 10.1007/s11060-017-2417.
    PubMed     Text format    


  32. GARZON-MUVDI T, Yang W, Lim M, Brem H, et al
    Atypical and anaplastic meningioma: outcomes in a population based study.
    J Neurooncol. 2017 Apr 20. doi: 10.1007/s11060-017-2436.
    PubMed     Text format     Abstract available


  33. KEIL VC, Pintea B, Gielen GH, Greschus S, et al
    Biopsy targeting with dynamic contrast-enhanced versus standard neuronavigation MRI in glioma: a prospective double-blinded evaluation of selection benefits.
    J Neurooncol. 2017 Apr 19. doi: 10.1007/s11060-017-2424.
    PubMed     Text format     Abstract available


  34. NIE E, Jin X, Wu W, Yu T, et al
    MiR-198 enhances temozolomide sensitivity in glioblastoma by targeting MGMT.
    J Neurooncol. 2017 Apr 19. doi: 10.1007/s11060-017-2425.
    PubMed     Text format     Abstract available


  35. HUANG X, Bai HX, Yang L
    ZEB1 expression in Chinese lower-grade gliomas.
    J Neurooncol. 2017 Apr 18. doi: 10.1007/s11060-017-2419.
    PubMed     Text format    


  36. BOISSELIER B, De Carli E, Rousseau A
    Molecular alterations in pediatric gliomatosis cerebri are similar to those in less invasive forms of pediatric diffuse glioma.
    J Neurooncol. 2017 Apr 18. doi: 10.1007/s11060-017-2432.
    PubMed     Text format    


  37. NGUYEN J, Hossain SS, Cooke JRN, Ellis JA, et al
    Flow arrest intra-arterial delivery of small TAT-decorated and neutral micelles to gliomas.
    J Neurooncol. 2017 Apr 18. doi: 10.1007/s11060-017-2429.
    PubMed     Text format     Abstract available


  38. RICHARDSON TE, Snuderl M, Serrano J, Karajannis MA, et al
    Rapid progression to glioblastoma in a subset of IDH-mutated astrocytomas: a genome-wide analysis.
    J Neurooncol. 2017 Apr 18. doi: 10.1007/s11060-017-2431.
    PubMed     Text format     Abstract available


  39. KIM Y, Do IG, Hong M, Suh YL, et al
    Negative prognostic effect of low nuclear GLI1 expression in glioblastomas.
    J Neurooncol. 2017 Apr 17. doi: 10.1007/s11060-017-2426.
    PubMed     Text format     Abstract available


  40. FAY-MCCLYMONT TB, Ploetz DM, Mabbott D, Walsh K, et al
    Long-term neuropsychological follow-up of young children with medulloblastoma treated with sequential high-dose chemotherapy and irradiation sparing approach.
    J Neurooncol. 2017 Apr 12. doi: 10.1007/s11060-017-2409.
    PubMed     Text format     Abstract available


  41. WIJNENGA MM, Mattni T, French PJ, Rutten GJ, et al
    Does early resection of presumed low-grade glioma improve survival? A clinical perspective.
    J Neurooncol. 2017 Apr 11. doi: 10.1007/s11060-017-2418.
    PubMed     Text format     Abstract available


  42. LI H, Lian J, Jin H, Wang W, et al
    Assessment of prognostic scores of brain metastases from lung adenocarcinoma with EGFR mutations.
    J Neurooncol. 2017 Apr 8. doi: 10.1007/s11060-017-2411.
    PubMed     Text format     Abstract available


  43. HOWARD SP, Krauze A, Chan MD, Tsien C, et al
    The evolving role for re-irradiation in the management of recurrent grade 4 glioma.
    J Neurooncol. 2017 Apr 6. doi: 10.1007/s11060-017-2392.
    PubMed     Text format     Abstract available


  44. TINI P, Nardone V, Pirtoli L
    Is there a potential role for EGFR expression to lead margin reduction in glioblastoma?
    J Neurooncol. 2017 Apr 5. doi: 10.1007/s11060-017-2406.
    PubMed     Text format    


  45. ELLINGSON BM, Chung C, Pope WB, Boxerman JL, et al
    Pseudoprogression, radionecrosis, inflammation or true tumor progression? challenges associated with glioblastoma response assessment in an evolving therapeutic landscape.
    J Neurooncol. 2017 Apr 5. doi: 10.1007/s11060-017-2375.
    PubMed     Text format     Abstract available


  46. AZOULAY M, Santos F, Shenouda G, Petrecca K, et al
    Benefit of re-operation and salvage therapies for recurrent glioblastoma multiforme: results from a single institution.
    J Neurooncol. 2017 Apr 3. doi: 10.1007/s11060-017-2383.
    PubMed     Text format     Abstract available


  47. LAZARI D, Alexiou GA, Markopoulos GS, Vartholomatos E, et al
    N-(p-coumaroyl) serotonin inhibits glioblastoma cells growth through triggering S-phase arrest and apoptosis.
    J Neurooncol. 2017 Apr 1. doi: 10.1007/s11060-017-2382.
    PubMed     Text format     Abstract available


    March 2017
  48. BRAUNSTEIN S, Raleigh D, Bindra R, Mueller S, et al
    Pediatric high-grade glioma: current molecular landscape and therapeutic approaches.
    J Neurooncol. 2017 Mar 29. doi: 10.1007/s11060-017-2393.
    PubMed     Text format     Abstract available


  49. ALTUNDAG K
    Radio-sensitising effect of T-DM1 should not be discarded for the efficacy of radiosurgery in the management of brain metastases in patients with HER2-positive metastatic breast cancer.
    J Neurooncol. 2017 Mar 23. doi: 10.1007/s11060-017-2405.
    PubMed     Text format    


  50. MASON M, Maurice C, McNamara MG, Tieu MT, et al
    Neutrophil-lymphocyte ratio dynamics during concurrent chemo-radiotherapy for glioblastoma is an independent predictor for overall survival.
    J Neurooncol. 2017 Mar 22. doi: 10.1007/s11060-017-2395.
    PubMed     Text format     Abstract available


  51. LIU H, Liu B, Hou X, Pang B, et al
    Overexpression of NIMA-related kinase 2 is associated with poor prognoses in malignant glioma.
    J Neurooncol. 2017 Mar 21. doi: 10.1007/s11060-017-2401.
    PubMed     Text format     Abstract available


  52. ERWOOD AA, Velazquez-Vega JE, Neill S, Solomon DA, et al
    Chordoid glioma of the third ventricle: report of a rapidly progressive case.
    J Neurooncol. 2017 Mar 18. doi: 10.1007/s11060-017-2399.
    PubMed     Text format     Abstract available


  53. ZHANG P, Sun S, Li N, Ho AS, et al
    Rutin increases the cytotoxicity of temozolomide in glioblastoma via autophagy inhibition.
    J Neurooncol. 2017 Mar 14. doi: 10.1007/s11060-017-2387.
    PubMed     Text format     Abstract available


  54. SINNADURAI M, McDonald KL
    Immune checkpoint inhibition and its relationship with hypermutation phenoytype as a potential treatment for Glioblastoma.
    J Neurooncol. 2017 Mar 14. doi: 10.1007/s11060-017-2390.
    PubMed     Text format     Abstract available


  55. DRESSLER EV, Dolecek TA, Liu M, Villano JL, et al
    Demographics, patterns of care, and survival in pediatric medulloblastoma.
    J Neurooncol. 2017 Mar 13. doi: 10.1007/s11060-017-2400.
    PubMed     Text format     Abstract available


  56. MEYER RM, Miller CA, Coughlin DJ, Rymarczuk G, et al
    Glioblastoma recurrence, progression, and dissemination as a purely subdural gliosarcoma.
    J Neurooncol. 2017 Mar 13. doi: 10.1007/s11060-017-2397.
    PubMed     Text format    


  57. KNEBEL FH, Uno M, Galatro TF, Belle LP, et al
    Serum amyloid A1 is upregulated in human glioblastoma.
    J Neurooncol. 2017 Mar 11. doi: 10.1007/s11060-017-2386.
    PubMed     Text format     Abstract available


  58. SATO A, Mizobuchi Y, Nakajima K, Shono K, et al
    Blocking COX-2 induces apoptosis and inhibits cell proliferation via the Akt/survivin- and Akt/ID3 pathway in low-grade-glioma.
    J Neurooncol. 2017 Mar 10. doi: 10.1007/s11060-017-2380.
    PubMed     Text format     Abstract available


  59. DONG X, Tamura K, Kobayashi D, Ando N, et al
    Erratum to: LAPTM4B-35 is a novel prognostic factor for glioblastoma.
    J Neurooncol. 2017 Mar 9. doi: 10.1007/s11060-017-2381.
    PubMed     Text format    


  60. QIAN JM, Mahajan A, Yu JB, Tsiouris AJ, et al
    Comparing available criteria for measuring brain metastasis response to immunotherapy.
    J Neurooncol. 2017 Mar 8. doi: 10.1007/s11060-017-2398.
    PubMed     Text format     Abstract available


  61. CORSO CD, Bindra RS, Mehta MP
    The role of radiation in treating glioblastoma: here to stay.
    J Neurooncol. 2017 Mar 7. doi: 10.1007/s11060-016-2348.
    PubMed     Text format     Abstract available


  62. FARINA P, Tabouret E, Lehmann P, Barrie M, et al
    Relationship between magnetic resonance imaging characteristics and plasmatic levels of MMP2 and MMP9 in patients with recurrent high-grade gliomas treated by Bevacizumab and Irinotecan.
    J Neurooncol. 2017 Mar 6. doi: 10.1007/s11060-017-2385.
    PubMed     Text format     Abstract available


  63. MINNITI G, Paolini S, D'Andrea G, Lanzetta G, et al
    Outcomes of postoperative stereotactic radiosurgery to the resection cavity versus stereotactic radiosurgery alone for melanoma brain metastases.
    J Neurooncol. 2017 Mar 4. doi: 10.1007/s11060-017-2394.
    PubMed     Text format     Abstract available


  64. DEB S, Pendharkar AV, Schoen MK, Altekruse S, et al
    The effect of socioeconomic status on gross total resection, radiation therapy and overall survival in patients with gliomas.
    J Neurooncol. 2017 Mar 3. doi: 10.1007/s11060-017-2391.
    PubMed     Text format     Abstract available


  65. ALTUNDAG K
    Tumor types, breast tumor subtypes and extension of systemic disease may influence outcome in cancer patients with brain metastases.
    J Neurooncol. 2017 Mar 2. doi: 10.1007/s11060-017-2402.
    PubMed     Text format    


    February 2017
  66. LUDWIG K, Kornblum HI
    Molecular markers in glioma.
    J Neurooncol. 2017 Feb 23. doi: 10.1007/s11060-017-2379.
    PubMed     Text format     Abstract available


  67. CHAMBERLAIN MC, Colman H, Kim BT, Raizer J, et al
    Salvage therapy with bendamustine for temozolomide refractory recurrent anaplastic gliomas: a prospective phase II trial.
    J Neurooncol. 2017 Feb 16. doi: 10.1007/s11060-016-2241.
    PubMed     Text format     Abstract available


  68. ROWSE AL, Gibson SA, Meares GP, Rajbhandari R, et al
    Protein kinase CK2 is important for the function of glioblastoma brain tumor initiating cells.
    J Neurooncol. 2017 Feb 8. doi: 10.1007/s11060-017-2378.
    PubMed     Text format     Abstract available


  69. LEE J, Solomon DA, Tihan T
    Erratum to: The role of histone modifications and telomere alterations in the pathogenesis of diffuse gliomas in adults and children.
    J Neurooncol. 2017 Feb 7. doi: 10.1007/s11060-017-2376.
    PubMed     Text format    


  70. SHABIHKHANI M, Telesca D, Movassaghi M, Naeini YB, et al
    Incidence, survival, pathology, and genetics of adult Latino Americans with glioblastoma.
    J Neurooncol. 2017 Feb 4. doi: 10.1007/s11060-017-2377.
    PubMed     Text format     Abstract available


  71. OORT Q, Dirven L, Meijer W, Sikkes SA, et al
    Development of a questionnaire measuring instrumental activities of daily living (IADL) in patients with brain tumors: a pilot study.
    J Neurooncol. 2017 Feb 1. doi: 10.1007/s11060-016-2352.
    PubMed     Text format     Abstract available


    January 2017
  72. NEILL E, Luks T, Dayal M, Phillips JJ, et al
    Quantitative multi-modal MR imaging as a non-invasive prognostic tool for patients with recurrent low-grade glioma.
    J Neurooncol. 2017 Jan 25. doi: 10.1007/s11060-016-2355.
    PubMed     Text format     Abstract available


  73. NAYAK L, de Groot J, Wefel JS, Cloughesy TF, et al
    Phase I trial of aflibercept (VEGF trap) with radiation therapy and concomitant and adjuvant temozolomide in patients with high-grade gliomas.
    J Neurooncol. 2017 Jan 23. doi: 10.1007/s11060-016-2357.
    PubMed     Text format     Abstract available


  74. MCGAHAN BG, Neilsen BK, Kelly DL, McComb RD, et al
    Assessment of vascularity in glioblastoma and its implications on patient outcomes.
    J Neurooncol. 2017 Jan 19. doi: 10.1007/s11060-016-2350.
    PubMed     Text format     Abstract available


  75. FLEISCHMANN DF, Unterrainer M, Bartenstein P, Belka C, et al
    18F-FET PET prior to recurrent high-grade glioma re-irradiation-additional prognostic value of dynamic time-to-peak analysis and early static summation images?
    J Neurooncol. 2017 Jan 19. doi: 10.1007/s11060-016-2366.
    PubMed     Text format     Abstract available


  76. MERKEL A, Soeldner D, Wendl C, Urkan D, et al
    Early postoperative tumor progression predicts clinical outcome in glioblastoma-implication for clinical trials.
    J Neurooncol. 2017 Jan 18. doi: 10.1007/s11060-016-2362.
    PubMed     Text format     Abstract available


  77. DONG X, Tamura K, Kobayashi D, Ando N, et al
    LAPTM4B-35 is a novel prognostic factor for glioblastoma.
    J Neurooncol. 2017 Jan 18. doi: 10.1007/s11060-017-2369.
    PubMed     Text format     Abstract available


  78. BAUGH J, Bartels U, Leach J, Jones B, et al
    The international diffuse intrinsic pontine glioma registry: an infrastructure to accelerate collaborative research for an orphan disease.
    J Neurooncol. 2017 Jan 16. doi: 10.1007/s11060-017-2372.
    PubMed     Text format     Abstract available


  79. CHENG W, Ren X, Zhang C, Han S, et al
    Expression and prognostic value of microRNAs in lower-grade glioma depends on IDH1/2 status.
    J Neurooncol. 2017 Jan 16. doi: 10.1007/s11060-016-2368.
    PubMed     Text format     Abstract available


  80. MUNTHE S, Halle B, Boldt HB, Christiansen H, et al
    Shift of microRNA profile upon glioma cell migration using patient-derived spheroids and serum-free conditions.
    J Neurooncol. 2017 Jan 13. doi: 10.1007/s11060-016-2356.
    PubMed     Text format     Abstract available


  81. XAVIER-MAGALHAES A, Oliveira AI, de Castro JV, Pojo M, et al
    Effects of the functional HOTAIR rs920778 and rs12826786 genetic variants in glioma susceptibility and patient prognosis.
    J Neurooncol. 2017 Jan 12. doi: 10.1007/s11060-016-2345.
    PubMed     Text format     Abstract available


  82. HE ZQ, Ke C, Al-Nahari F, Duan H, et al
    Low preoperative prognostic nutritional index predicts poor survival in patients with newly diagnosed high-grade gliomas.
    J Neurooncol. 2017 Jan 11. doi: 10.1007/s11060-016-2361.
    PubMed     Text format     Abstract available


  83. LUCAS JT JR, Serrano N, Kim H, Li X, et al
    11C-Methionine positron emission tomography delineates non-contrast enhancing tumor regions at high risk for recurrence in pediatric high-grade glioma.
    J Neurooncol. 2017 Jan 11. doi: 10.1007/s11060-016-2354.
    PubMed     Text format     Abstract available


  84. ARTZI M, Liberman G, Vaisman N, Bokstein F, et al
    Changes in cerebral metabolism during ketogenic diet in patients with primary brain tumors: 1H-MRS study.
    J Neurooncol. 2017 Jan 10. doi: 10.1007/s11060-016-2364.
    PubMed     Text format     Abstract available


  85. MISTRY AM, Dewan MC, White-Dzuro GA, Brinson PR, et al
    Decreased survival in glioblastomas is specific to contact with the ventricular-subventricular zone, not subgranular zone or corpus callosum.
    J Neurooncol. 2017 Jan 10. doi: 10.1007/s11060-017-2374.
    PubMed     Text format     Abstract available


  86. NA YC, Jung HH, Kim HR, Cho BC, et al
    Predictive factors of early distant brain failure after gamma knife radiosurgery alone in patients with brain metastases of non-small-cell lung cancer.
    J Neurooncol. 2017 Jan 10. doi: 10.1007/s11060-017-2373.
    PubMed     Text format     Abstract available


  87. CZARNEK N, Clark K, Peters KB, Mazurowski MA, et al
    Algorithmic three-dimensional analysis of tumor shape in MRI improves prognosis of survival in glioblastoma: a multi-institutional study.
    J Neurooncol. 2017 Jan 10. doi: 10.1007/s11060-016-2359.
    PubMed     Text format     Abstract available


  88. PINEL B, Duchesne M, Godet J, Milin S, et al
    Mesenchymal subtype of glioblastomas with high DNA-PKcs expression is associated with better response to radiotherapy and temozolomide.
    J Neurooncol. 2017 Jan 10. doi: 10.1007/s11060-016-2367.
    PubMed     Text format     Abstract available


  89. SAITO K, Ohta S, Kawakami Y, Yoshida K, et al
    Functional analysis of KIF20A, a potential immunotherapeutic target for glioma.
    J Neurooncol. 2017 Jan 9. doi: 10.1007/s11060-016-2360.
    PubMed     Text format     Abstract available


  90. LEE J, Solomon DA, Tihan T
    The role of histone modifications and telomere alterations in the pathogenesis of diffuse gliomas in adults and children.
    J Neurooncol. 2017 Jan 7. doi: 10.1007/s11060-016-2349.
    PubMed     Text format     Abstract available


    December 2016
  91. HAYASHI S, Kitamura Y, Hirose Y, Yoshida K, et al
    Molecular-genetic and clinicopathological prognostic factors in patients with gliomas showing total 1p19q loss: gain of chromosome 19p and histological grade III negatively correlate with patient's prognosis.
    J Neurooncol. 2016 Dec 26. doi: 10.1007/s11060-016-2344.
    PubMed     Text format     Abstract available


  92. RAO YJ, Hassanzadeh C, Fischer-Valuck B, Chicoine MR, et al
    Patterns of care and treatment outcomes of patients with Craniopharyngioma in the national cancer database.
    J Neurooncol. 2016 Dec 23. doi: 10.1007/s11060-016-2342.
    PubMed     Text format     Abstract available


  93. LI J, Ren S, Liu Y, Lian Z, et al
    Knockdown of NUPR1 inhibits the proliferation of glioblastoma cells via ERK1/2, p38 MAPK and caspase-3.
    J Neurooncol. 2016 Dec 20. doi: 10.1007/s11060-016-2337.
    PubMed     Text format     Abstract available


  94. PATEL KR, Burri SH, Boselli D, Symanowski JT, et al
    Comparing pre-operative stereotactic radiosurgery (SRS) to post-operative whole brain radiation therapy (WBRT) for resectable brain metastases: a multi-institutional analysis.
    J Neurooncol. 2016 Dec 20. doi: 10.1007/s11060-016-2334.
    PubMed     Text format     Abstract available


  95. GERAUD A, Xu HP, Beuzeboc P, Kirova YM, et al
    Preliminary experience of the concurrent use of radiosurgery and T-DM1 for brain metastases in HER2-positive metastatic breast cancer.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  96. WEIL AG, Wang AC, Westwick HJ, Ibrahim GM, et al
    Survival in pediatric medulloblastoma: a population-based observational study to improve prognostication.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  97. DARLIX A, Zouaoui S, Rigau V, Bessaoud F, et al
    Erratum to: Epidemiology for primary brain tumors: a nationwide population-based study.
    J Neurooncol. 2016.
    PubMed     Text format    


    November 2016
  98. BENNETT IE, Field KM, Hovens CM, Moffat BA, et al
    Early perfusion MRI predicts survival outcome in patients with recurrent glioblastoma treated with bevacizumab and carboplatin.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  99. WINTHER TL, Torp SH
    MCM7 expression is a promising predictor of recurrence in patients surgically resected for meningiomas.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  100. KARHADE AV, Fandino L, Gupta S, Cote DJ, et al
    Impact of operative length on post-operative complications in meningioma surgery: a NSQIP analysis.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  101. BALASUBRAMANIAN SK, Sharma M, Silva D, Karivedu V, et al
    Longitudinal experience with WHO Grade III (anaplastic) meningiomas at a single institution.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  102. AHLUWALIA MS, Bou-Anak S, Burgett ME, Sarmey N, et al
    Correlation of higher levels of soluble TNF-R1 with a shorter survival, independent of age, in recurrent glioblastoma.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  103. HUTTER G, Sailer M, Azad TD, von Bueren AO, et al
    Reverse phase protein arrays enable glioblastoma molecular subtyping.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  104. KALPATHY-CRAMER J, Chandra V, Da X, Ou Y, et al
    Phase II study of tivozanib, an oral VEGFR inhibitor, in patients with recurrent glioblastoma.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  105. DARLIX A, Zouaoui S, Rigau V, Bessaoud F, et al
    Epidemiology for primary brain tumors: a nationwide population-based study.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  106. GRIGUOLO G, Dieci MV, Giarratano T, Giorgi CA, et al
    Beyond breast specific-Graded Prognostic Assessment in patients with brain metastases from breast cancer: treatment impact on outcome.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  107. ISMAIL FS, Moinfar Z, Prochnow N, Dambach H, et al
    Dexamethasone and levetiracetam reduce hetero-cellular gap-junctional coupling between F98 glioma cells and glial cells in vitro.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  108. ZHANG J, Yao TW, Hashizume R, Hariono S, et al
    Combined BRAFV600E and MEK blockade for BRAFV600E-mutant gliomas.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  109. PHUPHANICH S, Raizer J, Chamberlain M, Canelos P, et al
    Phase II study of MEDI-575, an anti-platelet-derived growth factor-alpha antibody, in patients with recurrent glioblastoma.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  110. PERRINI P, Gambacciani C, Weiss A, Pasqualetti F, et al
    Survival outcomes following repeat surgery for recurrent glioblastoma: a single-center retrospective analysis.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  111. ZAKARIA R, Pomschar A, Jenkinson MD, Tonn JC, et al
    Use of diffusion-weighted MRI to modify radiosurgery planning in brain metastases may reduce local recurrence.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  112. HUANG J, Samson P, Perkins SM, Ansstas G, et al
    Impact of concurrent chemotherapy with radiation therapy for elderly patients with newly diagnosed glioblastoma: a review of the National Cancer Data Base.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  113. BO HK, Solheim O, Jakola AS, Kvistad KA, et al
    Intra-rater variability in low-grade glioma segmentation.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  114. DHAMI J, Chang E, Gambhir SS
    Withaferin A and its potential role in glioblastoma (GBM).
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  115. YANG JK, Yang JP, Tong J, Jing SY, et al
    Exosomal miR-221 targets DNM3 to induce tumor progression and temozolomide resistance in glioma.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  116. NAKAE S, Murayama K, Sasaki H, Kumon M, et al
    Prediction of genetic subgroups in adult supra tentorial gliomas by pre- and intraoperative parameters.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  117. HASEGAWA T, Kato T, Yamamoto T, Iizuka H, et al
    Multisession gamma knife surgery for large brain metastases.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  118. BUNEVICIUS A, Laws ER, Deltuva V, Tamasauskas A, et al
    Association of thyroid hormone concentrations with quality of life of primary brain tumor patients: a pilot study.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  119. PESSINA F, Navarria P, Cozzi L, Tomatis S, et al
    Role of surgical resection in recurrent glioblastoma: prognostic factors and outcome evaluation in an observational study.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  120. PAN E, Supko JG, Kaley TJ, Butowski NA, et al
    Phase I study of RO4929097 with bevacizumab in patients with recurrent malignant glioma.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  121. BORDIA R, Zhong H, Lee J, Weiss S, et al
    Melanoma brain metastases: correlation of imaging features with genomic markers and patient survival.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  122. BIRCKHEAD B, Sio TT, Pollock BE, Link MJ, et al
    Gamma Knife radiosurgery for neurofibromatosis type 2-associated meningiomas: a 22-year patient series.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  123. KUROKAWA C, Geekiyanage H, Allen C, Iankov I, et al
    Alisertib demonstrates significant antitumor activity in bevacizumab resistant, patient derived orthotopic models of glioblastoma.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


    October 2016
  124. MELLAI M, Annovazzi L, Senetta R, Dell'Aglio C, et al
    Diagnostic revision of 206 adult gliomas (including 40 oligoastrocytomas) based on ATRX, IDH1/2 and 1p/19q status.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  125. CIKANKOWITZ A, Clavreul A, Tetaud C, Lemaire L, et al
    Characterization of the distribution, retention, and efficacy of internal radiation of 188Re-lipid nanocapsules in an immunocompromised human glioblastoma model.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  126. RALEIGH DR, Tomlin B, Buono BD, Roddy E, et al
    Survival after chemotherapy and stem cell transplant followed by delayed craniospinal irradiation is comparable to upfront craniospinal irradiation in pediatric embryonal brain tumor patients.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  127. MAGILL ST, Theodosopoulos PV, McDermott MW
    Resection of falx and parasagittal meningioma: complication avoidance.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  128. INDINI A, Schiavello E, Biassoni V, Bergamaschi L, et al
    Long-term safety of growth hormone replacement therapy after childhood medulloblastoma and PNET: it is time to set aside old concerns.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  129. ARVOLD ND, Cefalu M, Wang Y, Zigler C, et al
    Comparative effectiveness of radiotherapy with vs. without temozolomide in older patients with glioblastoma.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  130. GILBERT MR, Pugh SL, Aldape K, Sorensen AG, et al
    NRG oncology RTOG 0625: a randomized phase II trial of bevacizumab with either irinotecan or dose-dense temozolomide in recurrent glioblastoma.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  131. MALLAWAARATCHY DM, Hallal S, Russell B, Ly L, et al
    Comprehensive proteome profiling of glioblastoma-derived extracellular vesicles identifies markers for more aggressive disease.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  132. SVENSSON A, Ramos-Moreno T, Eberstal S, Scheding S, et al
    Identification of two distinct mesenchymal stromal cell populations in human malignant glioma.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  133. DELLA PUPPA A, Lombardi G, Rossetto M, Rustemi O, et al
    Outcome of patients affected by newly diagnosed glioblastoma undergoing surgery assisted by 5-aminolevulinic acid guided resection followed by BCNU wafers implantation: a 3-year follow-up.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  134. TIVNAN A, Heilinger T, Lavelle EC, Prehn JH, et al
    Advances in immunotherapy for the treatment of glioblastoma.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  135. LIN AL, White M, Miller-Thomas MM, Fulton RS, et al
    Molecular and histologic characteristics of pseudoprogression in diffuse gliomas.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


    September 2016
  136. HEMPEL JM, Bisdas S, Schittenhelm J, Brendle C, et al
    Erratum to: In vivo molecular profiling of human glioma using diffusion kurtosis imaging.
    J Neurooncol. 2016.
    PubMed     Text format    


  137. CHABOT P, Hsia TC, Ryu JS, Gorbunova V, et al
    Veliparib in combination with whole-brain radiation therapy for patients with brain metastases from non-small cell lung cancer: results of a randomized, global, placebo-controlled study.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  138. MISTRY AM, Hale AT, Chambless LB, Weaver KD, et al
    Influence of glioblastoma contact with the lateral ventricle on survival: a meta-analysis.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  139. ZHU Y, Qiu Z, Zhang X, Qian F, et al
    Jab1 promotes glioma cell proliferation by regulating Siah1/beta-catenin pathway.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  140. WANG Y, Deng J, Guo G, Tong A, et al
    Clinical and prognostic role of annexin A2 in adamantinomatous craniopharyngioma.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  141. HICKMANN AK, Hechtner M, Nadji-Ohl M, Janko M, et al
    Evaluating patients for psychosocial distress and supportive care needs based on health-related quality of life in primary brain tumors: a prospective multicenter analysis of patients with gliomas in an outpatient setting.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  142. CONROY S, Wagemakers M, Walenkamp AM, Kruyt FA, et al
    Novel insights into vascularization patterns and angiogenic factors in glioblastoma subclasses.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  143. HAN SJ, Reis G, Kohanbash G, Shrivastav S, et al
    Expression and prognostic impact of immune modulatory molecule PD-L1 in meningioma.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  144. POLLACK IF, Jakacki RI, Butterfield LH, Hamilton RL, et al
    Antigen-specific immunoreactivity and clinical outcome following vaccination with glioma-associated antigen peptides in children with recurrent high-grade gliomas: results of a pilot study.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  145. AABERG-JESSEN C, Halle B, Jensen SS, Muller S, et al
    Comparative studies of TIMP-1 immunohistochemistry, TIMP-1 FISH analysis and plasma TIMP-1 in glioblastoma patients.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  146. BUJKO M, Kober P, Rusetska N, Wakula M, et al
    Aberrant DNA methylation of alternative promoter of DLC1 isoform 1 in meningiomas.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  147. MARATHE K, McVicar N, Li A, Bellyou M, et al
    Topiramate induces acute intracellular acidification in glioblastoma.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  148. YANAGIHARA TK, Saadatmand HJ, Wang TJ
    Reevaluating stereotactic radiosurgery for glioblastoma: new potential for targeted dose-escalation.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  149. HEMPEL JM, Bidsas S, Schittenhelm J, Brendle C, et al
    In vivo molecular profiling of human glioma using diffusion kurtosis imaging.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  150. SCHNELL O, Thorsteinsdottir J, Fleischmann DF, Lenski M, et al
    Re-irradiation strategies in combination with bevacizumab for recurrent malignant glioma.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  151. KOISO T, Yamamoto M, Kawabe T, Watanabe S, et al
    A case-matched study of stereotactic radiosurgery for patients with brain metastases: comparing treatment results for those with versus without neurological symptoms.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  152. ALSHEHRI N, Cote DJ, Hulou MM, Alghamdi A, et al
    Venous thromboembolism prophylaxis in brain tumor patients undergoing craniotomy: a meta-analysis.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


    August 2016
  153. O'NEILL AF, Qin L, Wen PY, de Groot JF, et al
    Demonstration of DCE-MRI as an early pharmacodynamic biomarker of response to VEGF Trap in glioblastoma.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  154. KAUR K, Kakkar A, Kumar A, Purkait S, et al
    Clinicopathological characteristics, molecular subgrouping, and expression of miR-379/miR-656 cluster (C14MC) in adult medulloblastomas.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  155. ELLIS JA, Cooke J, Singh-Moon RP, Wang M, et al
    Safety, feasibility, and optimization of intra-arterial mitoxantrone delivery to gliomas.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  156. SHAHAR T, Granit A, Zrihan D, Canello T, et al
    Expression level of miRNAs on chromosome 14q32.31 region correlates with tumor aggressiveness and survival of glioblastoma patients.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  157. COHEN-INBAR O, Xu Z, Dodson B, Rizvi T, et al
    Time-delayed contrast-enhanced MRI improves detection of brain metastases: a prospective validation of diagnostic yield.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  158. NESVICK CL, Zhang C, Edwards NA, Montgomery BK, et al
    ZEB1 expression is increased in IDH1-mutant lower-grade gliomas.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  159. TABOURET E, Denicolai E, Delfino C, Graillon T, et al
    Changes in PlGF and MET-HGF expressions in paired initial and recurrent glioblastoma.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  160. GINN KF, Fangman B, Terai K, Wise A, et al
    RalA is overactivated in medulloblastoma.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  161. DU Y, Pahernik S, Hadaschik B, Teber D, et al
    Impact of resection and systemic therapy on the survival of patients with brain metastasis of metastatic renal cell carcinoma.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  162. MIZUMOTO M, Yamamoto T, Ishikawa E, Matsuda M, et al
    Proton beam therapy with concurrent chemotherapy for glioblastoma multiforme: comparison of nimustine hydrochloride and temozolomide.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  163. BERK BA, Nagel S, Hering K, Paschke S, et al
    White matter lesions reduce number of brain metastases in different cancers: a high-resolution MRI study.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  164. LI C, Sun J, Xiang Q, Liang Y, et al
    Prognostic role of microRNA-21 expression in gliomas: a meta-analysis.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  165. BLUMENTHAL DT, Dvir A, Lossos A, Tzuk-Shina T, et al
    Clinical utility and treatment outcome of comprehensive genomic profiling in high grade glioma patients.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  166. MUNTHE S, Sorensen MD, Thomassen M, Burton M, et al
    Migrating glioma cells express stem cell markers and give rise to new tumors upon xenografting.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  167. HAN TJ, Cho BJ, Choi EJ, Kim DH, et al
    Inhibition of STAT3 enhances the radiosensitizing effect of temozolomide in glioblastoma cells in vitro and in vivo.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  168. MCCRACKEN DJ, Celano EC, Voloschin AD, Read WL, et al
    Phase I trial of dose-escalating metronomic temozolomide plus bevacizumab and bortezomib for patients with recurrent glioblastoma.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  169. KHALIFA J, Tensaouti F, Lotterie JA, Catalaa I, et al
    Do perfusion and diffusion MRI predict glioblastoma relapse sites following chemoradiation?
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


    July 2016
  170. TALARI NK, Panigrahi M, Madigubba S, Challa S, et al
    Altered tryptophan metabolism in human meningioma.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  171. FURTJES G, Kochling M, Peetz-Dienhart S, Wagner A, et al
    hTERT promoter methylation in meningiomas and central nervous hemangiopericytomas.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  172. KOTECHA R, Vogel S, Suh JH, Barnett GH, et al
    A cure is possible: a study of 10-year survivors of brain metastases.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  173. VAN LINDE ME, van der Mijn JC, Pham TV, Knol JC, et al
    Evaluation of potential circulating biomarkers for prediction of response to chemoradiation in patients with glioblastoma.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  174. RAHEJA A, Couldwell WT
    Microsurgical resection of skull base meningioma-expanding the operative corridor.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  175. BERGHOFF AS, Ricken G, Wilhelm D, Rajky O, et al
    Tumor infiltrating lymphocytes and PD-L1 expression in brain metastases of small cell lung cancer (SCLC).
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  176. CHOY CT, Wong CH, Loong HH
    Low expressions of ASS1 and OTC in glioblastoma suggest the potential clinical use of recombinant human arginase (rhArg).
    J Neurooncol. 2016.
    PubMed     Text format    


  177. SABEL M, Fleischhack G, Tippelt S, Gustafsson G, et al
    Relapse patterns and outcome after relapse in standard risk medulloblastoma: a report from the HIT-SIOP-PNET4 study.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  178. HERTENSTEIN A, Hielscher T, Menn O, Wiestler B, et al
    Impact of tapering and discontinuation of bevacizumab in patients with progressive glioblastoma.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  179. SUCHORSKA B, Hamisch C, Treuer H, Mahnkopf K, et al
    Stereotactic brachytherapy using iodine 125 seeds for the treatment of primary and recurrent anaplastic glioma WHO degrees III.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  180. JOY A, Kapoor M, Georges J, Butler L, et al
    The role of AKT isoforms in glioblastoma: AKT3 delays tumor progression.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  181. GESSI M, Pietsch T
    Deciphering the real incidence of medulloblastoma with extensive nodularity in adult patients.
    J Neurooncol. 2016.
    PubMed     Text format    


  182. LASOCKI A, Gaillard F, Tacey MA, Drummond KJ, et al
    The incidence and significance of multicentric noncontrast-enhancing lesions distant from a histologically-proven glioblastoma.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  183. WEATHERS SP, Han X, Liu DD, Conrad CA, et al
    A randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastoma.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  184. LI Y, Jiang T, Shao L, Liu Y, et al
    Mir-449a, a potential diagnostic biomarker for WNT group of medulloblastoma.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  185. PARK KS, Lee HW, Park SH, Park TI, et al
    The clinical significance of fascin expression in a newly diagnosed primary glioblastoma.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  186. GATELY L, Collins A, Murphy M, Dowling A, et al
    Age alone is not a predictor for survival in glioblastoma.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  187. DURATURO F, Liccardo R, Izzo P
    Coexistence of MLH3 germline variants in colon cancer patients belonging to families with Lynch syndrome-associated brain tumors.
    J Neurooncol. 2016.
    PubMed     Text format    


  188. HOLLA FK, Postma TJ, Blankenstein MA, van Mierlo TJ, et al
    Prognostic value of the S100B protein in newly diagnosed and recurrent glioma patients: a serial analysis.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  189. KAWAGUCHI T, Sonoda Y, Shibahara I, Saito R, et al
    Impact of gross total resection in patients with WHO grade III glioma harboring the IDH 1/2 mutation without the 1p/19q co-deletion.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  190. VERMA V, Mehta MP
    Clinical ramifications of "genomic staging" of low-grade gliomas.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  191. GUADAGNO E, Del Basso De Caro M, Pignatiello S, Sciammarella C, et al
    Expression of p40 (Np63) protein in meningiomas, an unexpected finding: immunohistochemical study and evaluation of its possible prognostic role.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  192. NOLEN SC, Lee B, Shantharam S, Yu HJ, et al
    The effects of sequential treatments on hippocampal volumes in malignant glioma patients.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  193. NAKAZAWA T, Nakamura M, Matsuda R, Nishimura F, et al
    Antitumor effects of minodronate, a third-generation nitrogen-containing bisphosphonate, in synergy with gammadeltaT cells in human glioblastoma in vitro and in vivo.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  194. HAMILTON BE, Woltjer RL, Prola-Netto J, Nesbit GM, et al
    Ferumoxytol-enhanced MRI differentiation of meningioma from dural metastases: a pilot study with immunohistochemical observations.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  195. JAJAMOVICH GH, Valiathan CR, Cristescu R, Somayajula S, et al
    Integrative analysis of diffusion-weighted MRI and genomic data to inform treatment of glioblastoma.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  196. KNUDSEN-BAAS KM, Engeland A, Gilhus NE, Storstein AM, et al
    Does the choice of antiepileptic drug affect survival in glioblastoma patients?
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


    June 2016
  197. SALLOUM R, Hummel TR, Kumar SS, Dorris K, et al
    A molecular biology and phase II study of imetelstat (GRN163L) in children with recurrent or refractory central nervous system malignancies: a pediatric brain tumor consortium study.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  198. CIEZKA M, Acosta M, Herranz C, Canals JM, et al
    Development of a transplantable glioma tumour model from genetically engineered mice: MRI/MRS/MRSI characterisation.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  199. SUH CH, Jung SC, Kim KW, Pyo J, et al
    The detectability of brain metastases using contrast-enhanced spin-echo or gradient-echo images: a systematic review and meta-analysis.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  200. KRIVOSHEYA D, Prabhu SS, Weinberg JS, Sawaya R, et al
    Technical principles in glioma surgery and preoperative considerations.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  201. SHIH KC, Chowdhary S, Rosenblatt P, Weir AB 3rd, et al
    A phase II trial of bevacizumab and everolimus as treatment for patients with refractory, progressive intracranial meningioma.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  202. BRACCI S, Laigle-Donadey F, Hitchcock K, Duran-Pena A, et al
    Role of irradiation for patients over 80 years old with glioblastoma: a retrospective cohort study.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  203. DESHPANDE RP, Babu D, Panigrahi M, Chandra Sekhar YB, et al
    Brain tumors incidences and a retrospective clinical analysis from a tertiary hospital in India.
    J Neurooncol. 2016.
    PubMed     Text format    


  204. CHAMPEAUX C, Wilson E, Shieff C, Khan AA, et al
    WHO grade II meningioma: a retrospective study for outcome and prognostic factor assessment.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  205. WAN MJ, Ullrich NJ, Manley PE, Kieran MW, et al
    Long-term visual outcomes of optic pathway gliomas in pediatric patients without neurofibromatosis type 1.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  206. NEAL A, Yuen T, Bjorksten AR, Kwan P, et al
    Peritumoural glutamate correlates with post-operative seizures in supratentorial gliomas.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  207. RAIZER JJ, Chandler JP, Ferrarese R, Grimm SA, et al
    A phase II trial evaluating the effects and intra-tumoral penetration of bortezomib in patients with recurrent malignant gliomas.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  208. BAUMSTARCK K, Leroy T, Hamidou Z, Tabouret E, et al
    Coping with a newly diagnosed high-grade glioma: patient-caregiver dyad effects on quality of life.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  209. SAFAEE MM, Englot DJ, Han SJ, Lawton MT, et al
    The transsylvian approach for resection of insular gliomas: technical nuances of splitting the Sylvian fissure.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  210. VON BUEREN AO, Seidel C, Friedrich C
    Comment on: Adjuvant chemotherapy in adult medulloblastoma: is it an option for average-risk patients?
    J Neurooncol. 2016.
    PubMed     Text format    


  211. HOFFMANN A, Brentrup A, Muller HL
    First report on spinal metastasis in childhood-onset craniopharyngioma.
    J Neurooncol. 2016.
    PubMed     Text format    


  212. TUNG JN, Ko CP, Yang SF, Cheng CW, et al
    Inhibition of pentraxin 3 in glioma cells impairs proliferation and invasion in vitro and in vivo.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  213. MANDEL JJ, Cachia D, Liu D, Wilson C, et al
    Impact of IDH1 mutation status on outcome in clinical trials for recurrent glioblastoma.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  214. CHAKRABORTY S, Filippi CG, Wong T, Ray A, et al
    Erratum to: Superselective intraarterial cerebral infusion of cetuximab after osmotic blood/brain barrier disruption for recurrent malignant glioma: phase I study.
    J Neurooncol. 2016.
    PubMed     Text format    


    May 2016
  215. BOONE M, Roussel M, Chauffert B, Le Gars D, et al
    Prevalence and profile of cognitive impairment in adult glioma: a sensitivity analysis.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  216. FAN X, Wang Y, Liu Y, Liu X, et al
    Brain regions associated with telomerase reverse transcriptase promoter mutations in primary glioblastomas.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  217. ALLI S, Isik S, Rutka JT
    Microsurgical removal of craniopharyngioma: endoscopic and transcranial techniques for complication avoidance.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  218. IWADATE Y, Matsutani T, Hirono S, Shinozaki N, et al
    Transforming growth factor-beta and stem cell markers are highly expressed around necrotic areas in glioblastoma.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  219. SCHAUB C, Tichy J, Schafer N, Franz K, et al
    Prognostic factors in recurrent glioblastoma patients treated with bevacizumab.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  220. ACKER G, Palumbo A, Neri D, Vajkoczy P, et al
    F8-SIP mediated targeted photodynamic therapy leads to microvascular dysfunction and reduced glioma growth.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  221. CARCELLER F, Fowkes LA, Khabra K, Moreno L, et al
    Pseudoprogression in children, adolescents and young adults with non-brainstem high grade glioma and diffuse intrinsic pontine glioma.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  222. VELDHUIJZEN VAN ZANTEN SE, Cruz O, Kaspers GJ, Hargrave DR, et al
    State of affairs in use of steroids in diffuse intrinsic pontine glioma: an international survey and a review of the literature.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  223. LI J, Tang C, Li L, Li R, et al
    Quercetin blocks t-AUCB-induced autophagy by Hsp27 and Atg7 inhibition in glioblastoma cells in vitro.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  224. HERVEY-JUMPER SL, Berger MS
    Maximizing safe resection of low- and high-grade glioma.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  225. NASR ZG, Paravattil B, Wilby KJ
    Levetiracetam for seizure prevention in brain tumor patients: a systematic review.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  226. LOMBARDI G, Bellu L, Pambuku A, Della Puppa A, et al
    Clinical outcome of an alternative fotemustine schedule in elderly patients with recurrent glioblastoma: a mono-institutional retrospective study.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  227. MICHAUD K, Duffau H
    Surgery of insular and paralimbic diffuse low-grade gliomas: technical considerations.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  228. ZIU M, Olson JJ
    Update on the evidence-based clinical practice parameter guidelines for the treatment of adults with diffuse low grade glioma: the role of initial chemotherapy.
    J Neurooncol. 2016.
    PubMed     Text format    


  229. PAJTLER KW, Tippelt S, Siegler N, Reichling S, et al
    Intraventricular etoposide safety and toxicity profile in children and young adults with refractory or recurrent malignant brain tumors.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  230. LIM J, Cho K
    The modified lateral supraorbital approach for tumors of the petroclival junction extending into the anterior cerebellopontine area.
    J Neurooncol. 2016;127:541-50.
    PubMed     Text format     Abstract available


  231. SAVELLI G, Bartolomei M, Bignardi M
    Somatostatin receptors imaging and therapy in a patient affected by esthesioneuroblastoma with meningeal metastases. A classic example of theranostic approach.
    J Neurooncol. 2016;127:617-9.
    PubMed     Text format    


  232. BECKER J, Steinmann E, Konemann M, Gabske S, et al
    Cognitive screening in patients with intracranial tumors: validation of the BCSE.
    J Neurooncol. 2016;127:559-67.
    PubMed     Text format     Abstract available


  233. VAN DE NES J, Gessi M, Sucker A, Moller I, et al
    Targeted next generation sequencing reveals unique mutation profile of primary melanocytic tumors of the central nervous system.
    J Neurooncol. 2016;127:435-44.
    PubMed     Text format     Abstract available


    April 2016
  234. KAPREALIAN T, Raleigh DR, Sneed PK, Nabavizadeh N, et al
    Parameters influencing local control of meningiomas treated with radiosurgery.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  235. GUNN ME, Lahdesmaki T, Malila N, Arola M, et al
    Use of endocrinological and neurological medication among 5-year survivors of young onset brain tumors.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  236. CHOI SH, Jung SC, Kim KW, Lee JY, et al
    Perfusion MRI as the predictive/prognostic and pharmacodynamic biomarkers in recurrent malignant glioma treated with bevacizumab: a systematic review and a time-to-event meta-analysis.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  237. SMITH AW, Mehta MP, Wernicke AG
    Neural stem cells, the subventricular zone and radiotherapy: implications for treating glioblastoma.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  238. GHUMMAN S, Fortin D, Noel-Lamy M, Cunnane SC, et al
    Exploratory study of the effect of brain tumors on the default mode network.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  239. HALLE B, Thomassen M, Venkatesan R, Kaimal V, et al
    Shift of microRNA profile upon orthotopic xenografting of glioblastoma spheroid cultures.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  240. YE J, Lv G, Qian J, Zhu J, et al
    Clinical features and prognostic factors of WHO II and III adult spinal meningiomas: analysis of 25 cases in a single center.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  241. MESKAL I, Gehring K, Rutten GM, Sitskoorn MM, et al
    Cognitive functioning in meningioma patients: a systematic review.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


    March 2016
  242. NETSON KL, Ashford JM, Skinner T, Carty L, et al
    Executive dysfunction is associated with poorer health-related quality of life in pediatric brain tumor survivors.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  243. BRIGLIADORI G, Foca F, Dall'Agata M, Rengucci C, et al
    Defining the cutoff value of MGMT gene promoter methylation and its predictive capacity in glioblastoma.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  244. BUGLIONE M, Pedretti S, Poliani PL, Liserre R, et al
    Pattern of relapse of glioblastoma multiforme treated with radical radio-chemotherapy: could a margin reduction be proposed.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  245. NOLL KR, Ziu M, Weinberg JS, Wefel JS, et al
    Neurocognitive functioning in patients with glioma of the left and right temporal lobes.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  246. LIU Y, Fan C, Pu L, Wei C, et al
    Phloretin induces cell cycle arrest and apoptosis of human glioblastoma cells through the generation of reactive oxygen species.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  247. SHIN JY, Kizilbash SH, Robinson SI, Uhm JH, et al
    Seizures in patients with primary brain tumors: what is their psychosocial impact?
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  248. RHOME R, Fisher R, Hormigo A, Parikh RR, et al
    Disparities in receipt of modern concurrent chemoradiotherapy in glioblastoma.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  249. HONG L, Ya-Wei L, Hai W, Qiang Z, et al
    MiR-519a functions as a tumor suppressor in glioma by targeting the oncogenic STAT3 pathway.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  250. WARDAK Z, Augustyn A, Zhu H, Mickey BE, et al
    Pre-treatment factors associated with detecting additional brain metastases at stereotactic radiosurgery.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  251. HUANG J, Campian JL, Gujar AD, Tran DD, et al
    A phase I study to repurpose disulfiram in combination with temozolomide to treat newly diagnosed glioblastoma after chemoradiotherapy.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  252. LI Y, Pan W, Connolly ID, Reddy S, et al
    Tumor DNA in cerebral spinal fluid reflects clinical course in a patient with melanoma leptomeningeal brain metastases.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  253. HAMARD L, Ratel D, Selek L, Berger F, et al
    The brain tissue response to surgical injury and its possible contribution to glioma recurrence.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  254. BLUMENTHAL DT, Mendel L, Bokstein F
    Erratum to: The optimal regimen of bevacizumab for recurrent glioblastoma: does dose matter?
    J Neurooncol. 2016.
    PubMed     Text format    


  255. LEE J, Kim E, Ryu SW, Choi C, et al
    Combined inhibition of vascular endothelial growth factor receptor signaling with temozolomide enhances cytotoxicity against human glioblastoma cells via downregulation of Neuropilin-1.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  256. CHAKRABORTY S, Filippi CG, Wong T, Ray A, et al
    Superselective intraarterial cerebral infusion of cetuximab after osmotic blood/brain barrier disruption for recurrent malignant glioma: phase I study.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  257. FRANCESCHI E, Depenni R, Paccapelo A, Ermani M, et al
    Which elderly newly diagnosed glioblastoma patients can benefit from radiotherapy and temozolomide? A PERNO prospective study.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  258. FRANCESCHI E, Bartolotti M, Paccapelo A, Marucci G, et al
    Adjuvant chemotherapy in adult medulloblastoma: is it an option for average-risk patients?
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  259. KHASRAW M, Lee A, McCowatt S, Kerestes Z, et al
    Cilengitide with metronomic temozolomide, procarbazine, and standard radiotherapy in patients with glioblastoma and unmethylated MGMT gene promoter in ExCentric, an open-label phase II trial.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  260. DUERINCK J, Du Four S, Vandervorst F, D'Haene N, et al
    Randomized phase II study of axitinib versus physicians best alternative choice of therapy in patients with recurrent glioblastoma.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


    February 2016
  261. PANOSYAN EH, Lasky JL, Lin HJ, Lai A, et al
    Clinical aggressiveness of malignant gliomas is linked to augmented metabolism of amino acids.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  262. SCHWARTZ C, Kreth FW
    Comment on: the role of biopsy in the management of patients with presumed diffuse low grade glioma: a systematic review and evidence-based clinical practice guideline.
    J Neurooncol. 2016.
    PubMed     Text format    


  263. WU X, Wu F, Xu D, Zhang T, et al
    Erratum to: Prognostic significance of stem cell marker CD133 determined by promoter methylation but not by immunohistochemical expression in malignant gliomas.
    J Neurooncol. 2016.
    PubMed     Text format    


  264. ROSTAMI R, Mittal S, Rostami P, Tavassoli F, et al
    Brain metastasis in breast cancer: a comprehensive literature review.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  265. STEFFENS R, Semrau S, Lahmer G, Putz F, et al
    Recurrent glioblastoma: who receives tumor specific treatment and how often?
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  266. NGUYEN J, Cooke JR, Ellis JA, Deci M, et al
    Cationizable lipid micelles as vehicles for intraarterial glioma treatment.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  267. TORRES A, Vargas Y, Uribe D, Carrasco C, et al
    Pro-apoptotic and anti-angiogenic properties of the alpha /beta-thujone fraction from Thuja occidentalis on glioblastoma cells.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  268. JUE TR, McDonald KL
    The challenges associated with molecular targeted therapies for glioblastoma.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  269. FROSINA G
    Positron emission tomography of high-grade gliomas.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  270. GZELL CE, Wheeler HR, McCloud P, Kastelan M, et al
    Small increases in enhancement on MRI may predict survival post radiotherapy in patients with glioblastoma.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  271. HANDS JR, Clemens G, Stables R, Ashton K, et al
    Brain tumour differentiation: rapid stratified serum diagnostics via attenuated total reflection Fourier-transform infrared spectroscopy.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  272. WOLF A, Zia S, Verma R, Pavlick A, et al
    Impact on overall survival of the combination of BRAF inhibitors and stereotactic radiosurgery in patients with melanoma brain metastases.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  273. FARZIN M, Molls M, Kampfer S, Astner S, et al
    Optic toxicity in radiation treatment of meningioma: a retrospective study in 213 patients.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  274. BALANA C, De Las Penas R, Sepulveda JM, Gil-Gil MJ, et al
    Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma: the GENOM 009 randomized phase II trial.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  275. VAN OMMEREN R, Staudt MD, Xu H, Hebb MO, et al
    Advances in HSP27 and HSP90-targeting strategies for glioblastoma.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  276. O'LEARY B, Mandeville HC, Fersht N, Solda F, et al
    Craniospinal irradiation with concomitant and adjuvant temozolomide-a feasibility assessment of toxicity in patients with glioblastoma with a PNET component.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  277. MITSUYA K, Nakasu Y, Narita Y, Nakasu S, et al
    "Comet tail sign": A pitfall of post-gadolinium magnetic resonance imaging findings for metastatic brain tumors.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  278. GHASIMI S, Wibom C, Dahlin AM, Brannstrom T, et al
    Genetic risk variants in the CDKN2A/B, RTEL1 and EGFR genes are associated with somatic biomarkers in glioma.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  279. REDJAL N, Reinshagen C, Le A, Walcott BP, et al
    Valproic acid, compared to other antiepileptic drugs, is associated with improved overall and progression-free survival in glioblastoma but worse outcome in grade II/III gliomas treated with temozolomide.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  280. MULDOON LL, Pagel MA, Netto JP, Neuwelt EA, et al
    Intra-arterial administration improves temozolomide delivery and efficacy in a model of intracerebral metastasis, but has unexpected brain toxicity.
    J Neurooncol. 2016;126:447-54.
    PubMed     Text format     Abstract available


  281. LOSA M, Bogazzi F, Cannavo S, Ceccato F, et al
    Temozolomide therapy in patients with aggressive pituitary adenomas or carcinomas.
    J Neurooncol. 2016;126:519-25.
    PubMed     Text format     Abstract available


  282. CHAMBERLAIN MC
    High-dose cytarabine salvage therapy for recurrent primary CNS lymphoma.
    J Neurooncol. 2016;126:545-50.
    PubMed     Text format     Abstract available


  283. TAIEB D, Barlier A, Yang C, Pertuit M, et al
    Somatic gain-of-function HIF2A mutations in sporadic central nervous system hemangioblastomas.
    J Neurooncol. 2016;126:473-81.
    PubMed     Text format     Abstract available


    January 2016
  284. AL-GHAFARI AB, Punjaruk W, Storer LC, Carrier DJ, et al
    Long-term exposure to irinotecan reduces cell migration in glioma cells.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  285. ADEBERG S, Diehl C, Jung CS, Rieken S, et al
    Is a modification of the radiotherapeutic target volume necessary after resection of glioblastomas with opening of the ventricles?
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  286. KANTELHARDT SR, Kalasauskas D, Konig K, Kim E, et al
    In vivo multiphoton tomography and fluorescence lifetime imaging of human brain tumor tissue.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  287. ZOLAL A, Juratli TA, Linn J, Podlesek D, et al
    Enhancing tumor apparent diffusion coefficient histogram skewness stratifies the postoperative survival in recurrent glioblastoma multiforme patients undergoing salvage surgery.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  288. SHI W, Palmer JD, Werner-Wasik M, Andrews DW, et al
    Phase I trial of panobinostat and fractionated stereotactic re-irradiation therapy for recurrent high grade gliomas.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  289. DASGUPTA T, Olow AK, Yang X, Hashizume R, et al
    Erratum to: Survival advantage combining a BRAF inhibitor and radiation in BRAF V600E-mutant glioma.
    J Neurooncol. 2016.
    PubMed     Text format    


  290. LEU S, von Felten S, Frank S, Boulay JL, et al
    IDH mutation is associated with higher risk of malignant transformation in low-grade glioma.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  291. YUAN R, Yamada A, Weber B, Ho C, et al
    Radiographic patterns and survival of patients with early and late brain metastases in EGFR wild type and mutant non small cell lung cancer.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  292. LEE CY, Lai HY, Chiu A, Chan SH, et al
    The effects of antiepileptic drugs on the growth of glioblastoma cell lines.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  293. WU X, Langwu F, Xu D, Zhang T, et al
    Prognostic significance of stem cell marker CD133 determined by promoter methylation but not by immunohistochemical expression in malignant gliomas.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  294. ARTZI M, Liberman G, Nadav G, Blumenthal DT, et al
    Differentiation between treatment-related changes and progressive disease in patients with high grade brain tumors using support vector machine classification based on DCE MRI.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  295. EVANS SM, Putt M, Yang XY, Lustig RA, et al
    Initial evidence that blood-borne microvesicles are biomarkers for recurrence and survival in newly diagnosed glioblastoma patients.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  296. KIM B, Kim K, Im KH, Kim JH, et al
    Multiparametric MR imaging of tumor response to intraarterial chemotherapy in orthotopic xenograft models of human metastatic brain tumor.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  297. MUSIC D, Dahlrot RH, Hermansen SK, Hjelmborg J, et al
    Expression and prognostic value of the WEE1 kinase in gliomas.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  298. CORREA DD, Kryza-Lacombe M, Baser RE, Beal K, et al
    Cognitive effects of donepezil therapy in patients with brain tumors: a pilot study.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  299. VILAS-BOAS FA, da Silva AM, de Sousa LP, Lima KM, et al
    Impairment of stress granule assembly via inhibition of the eIF2alpha phosphorylation sensitizes glioma cells to chemotherapeutic agents.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  300. DE VRIES CL, Linn SC, Brandsma D
    Response of symptomatic brain metastases from HER-2 overexpressing breast cancer with T-DM1.
    J Neurooncol. 2016.
    PubMed     Text format    


  301. KOOB M, Girard N, Ghattas B, Fellah S, et al
    The diagnostic accuracy of multiparametric MRI to determine pediatric brain tumor grades and types.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  302. COHEN IJ
    Reply to: methotrexate administration directly into the fourth ventricle in children with malignant fourth ventricular brain tumors: a pilot clinical trial.
    J Neurooncol. 2016.
    PubMed     Text format    


  303. SACCONI B, Raad RA, Lee J, Fine H, et al
    Concurrent functional and metabolic assessment of brain tumors using hybrid PET/MR imaging.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  304. MENDEZ JS, Govindan A, Leong J, Gao F, et al
    Association between treatment-related lymphopenia and overall survival in elderly patients with newly diagnosed glioblastoma.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  305. WERNICKE AG, Yondorf MZ, Parashar B, Nori D, et al
    The cost-effectiveness of surgical resection and cesium-131 intraoperative brachytherapy versus surgical resection and stereotactic radiosurgery in the treatment of metastatic brain tumors.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  306. HE M, Luo M, Liu Q, Chen J, et al
    Combination treatment with fasudil and clioquinol produces synergistic anti-tumor effects in U87 glioblastoma cells by activating apoptosis and autophagy.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  307. MCCURDY MD, Rane S, Daly BP, Jacobson LA, et al
    Associations among treatment-related neurological risk factors and neuropsychological functioning in survivors of childhood brain tumor.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  308. ZHANG G, Huang S, Zhang J, Wu Z, et al
    Clinical outcome of gliosarcoma compared with glioblastoma multiforme: a clinical study in Chinese patients.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  309. HUANG RQ, Shi DL, Huang W, Chen F, et al
    Increased expression of phosphatidylethanolamine-binding protein 4 (PEBP4) strongly associates with human gliomas grade.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  310. TAKEUCHI H, Kitai R, Hosoda T, Yamada S, et al
    Clinicopathologic features of small cell glioblastomas.
    J Neurooncol. 2016.
    PubMed     Text format     Abstract available


  311. WALBERT T, Glantz M, Schultz L, Puduvalli VK, et al
    Impact of provider level, training and gender on the utilization of palliative care and hospice in neuro-oncology: a North-American survey.
    J Neurooncol. 2016;126:337-45.
    PubMed     Text format     Abstract available


  312. GILARD V, Alexandru C, Proust F, Derrey S, et al
    Pituitary metastasis: is there still a place for neurosurgical treatment?
    J Neurooncol. 2016;126:219-24.
    PubMed     Text format     Abstract available


    December 2015
  313. DT B, L M, F B
    The optimal regimen of bevacizumab for recurrent glioblastoma: does dose matter?
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  314. SELIGER C, Meier CR, Jick SS, Uhl M, et al
    Use of cardiac glycosides and risk of glioma.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  315. HANNA A, Boggs DH, Kwok Y, Simard M, et al
    What predicts early volumetric edema increase following stereotactic radiosurgery for brain metastases?
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  316. BUMES E, Rzonsa S, Hutterer M, Proescholdt M, et al
    Adverse event grading following CTCAE v3.0 underestimates hypertensive side effects in patients with glioma treated with Bevacizumab.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  317. LIU H, Hou H, Cheng J
    Primary Burkitt lymphoma of the fourth ventricle mimicking a medulloblastoma in a child.
    J Neurooncol. 2015.
    PubMed     Text format    


  318. CHANDRA S, Parker DJ, Barth RF, Pannullo SC, et al
    Quantitative imaging of magnesium distribution at single-cell resolution in brain tumors and infiltrating tumor cells with secondary ion mass spectrometry (SIMS).
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  319. LIU Y, Hou X, Liu M, Yang Z, et al
    XBP1 silencing decreases glioma cell viability and glycolysis possibly by inhibiting HK2 expression.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  320. PHAM A, Yondorf MZ, Parashar B, Scheff RJ, et al
    Neurocognitive function and quality of life in patients with newly diagnosed brain metastasis after treatment with intra-operative cesium-131 brachytherapy: a prospective trial.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  321. CHANG E, Pohling C, Natarajan A, Witney TH, et al
    AshwaMAX and Withaferin A inhibits gliomas in cellular and murine orthotopic models.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  322. NAKASHIMA S, Sugita Y, Miyoshi H, Arakawa F, et al
    Endothelin B receptor expression in malignant gliomas: the perivascular immune escape mechanism of gliomas.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  323. ODIA Y, Iwamoto FM, Moustakas A, Fraum TJ, et al
    A phase II trial of enzastaurin (LY317615) in combination with bevacizumab in adults with recurrent malignant gliomas.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  324. LANGBECKER D, Yates P
    Primary brain tumor patients' supportive care needs and multidisciplinary rehabilitation, community and psychosocial support services: awareness, referral and utilization.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  325. LAWRENCE JE, Steele CJ, Rovin RA, Belton RJ Jr, et al
    Dexamethasone alone and in combination with desipramine, phenytoin, valproic acid or levetiracetam interferes with 5-ALA-mediated PpIX production and cellular retention in glioblastoma cells.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  326. LAMANO JB, Ampie L, Choy W, Kesavabhotla K, et al
    Immunomonitoring in glioma immunotherapy: current status and future perspectives.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  327. ROCK J
    Low grade glioma guidelines: Foreword.
    J Neurooncol. 2015;125:447-8.
    PubMed     Text format    


  328. HUMMEL TR, Salloum R, Drissi R, Kumar S, et al
    A pilot study of bevacizumab-based therapy in patients with newly diagnosed high-grade gliomas and diffuse intrinsic pontine gliomas.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


    November 2015
  329. LEE WH, Oh BM, Seo HG, Kim SK, et al
    One-year outcome of postoperative swallowing impairment in pediatric patients with posterior fossa brain tumor.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  330. YOMO S, Hayashi M
    Salvage stereotactic radiosurgery with adjuvant use of bevacizumab for heavily treated recurrent brain metastases: a preliminary report.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  331. GRUBB CS, Jani A, Wu CC, Saad S, et al
    Breast cancer subtype as a predictor for outcomes and control in the setting of brain metastases treated with stereotactic radiosurgery.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  332. HEILAND DH, Masalha W, Franco P, Machein MR, et al
    Progression-free and overall survival in patients with recurrent Glioblastoma multiforme treated with last-line bevacizumab versus bevacizumab/lomustine.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  333. HORVATH A, Perlaki G, Toth A, Orsi G, et al
    Increased diffusion in the normal appearing white matter of brain tumor patients: is this just tumor infiltration?
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  334. PELLERINO A, Soffietti R, Ruda R
    Temozolomide for recurrent meningiomas: a case-report with unexpected clinical and radiological response.
    J Neurooncol. 2015.
    PubMed     Text format    


  335. WATANABE A, Muragaki Y, Maruyama T, Shinoda J, et al
    Usefulness of C-methionine positron emission tomography for treatment-decision making in cases of non-enhancing glioma-like brain lesions.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  336. PARK HH, Roh TH, Kang SG, Kim EH, et al
    Pseudoprogression in glioblastoma patients: the impact of extent of resection.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  337. NENCHA U, Rahimian A, Giry M, Sechi A, et al
    TERT promoter mutations and rs2853669 polymorphism: prognostic impact and interactions with common alterations in glioblastomas.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  338. HENKER C, Kriesen T, Furst K, Goody D, et al
    Effect of 10 different polymorphisms on preoperative volumetric characteristics of glioblastoma multiforme.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  339. BOKSTEIN F, Blumenthal DT, Corn BW, Gez E, et al
    Stereotactic radiosurgery (SRS) in high-grade glioma: judicious selection of small target volumes improves results.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  340. KAST RE, Ramiro S, Llado S, Toro S, et al
    Antitumor action of temozolomide, ritonavir and aprepitant against human glioma cells.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  341. TANG C, Zhang ZY, Chen LC, Sun Z, et al
    Subgroup characteristics of insular low-grade glioma based on clinical and molecular analysis of 42 cases.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  342. PICHT T, Frey D, Thieme S, Kliesch S, et al
    Presurgical navigated TMS motor cortex mapping improves outcome in glioblastoma surgery: a controlled observational study.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  343. HAMZA MA, Kamiya-Matsuoka C, Liu D, Yuan Y, et al
    Outcome of patients with malignant glioma and synchronous or metachronous non-central nervous system primary neoplasms.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  344. DHRUV HD, Roos A, Tomboc PJ, Tuncali S, et al
    Propentofylline inhibits glioblastoma cell invasion and survival by targeting the TROY signaling pathway.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  345. KOEKKOEK JA, Dirven L, Heimans JJ, Postma TJ, et al
    Seizure reduction is a prognostic marker in low-grade glioma patients treated with temozolomide.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  346. SOCHA J, Kepka L, Ghosh S, Roa W, et al
    Outcome of treatment of recurrent glioblastoma multiforme in elderly and/or frail patients.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  347. WOJTON J, Meisen WH, Kaur B
    How to train glioma cells to die: molecular challenges in cell death.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  348. ZHANG R, Saito R, Shibahara I, Sugiyama S, et al
    Temozolomide reverses doxorubicin resistance by inhibiting P-glycoprotein in malignant glioma cells.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  349. RYKEN TC, Parney I, Buatti J, Kalkanis SN, et al
    The role of radiotherapy in the management of patients with diffuse low grade glioma : A systematic review and evidence-based clinical practice guideline.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  350. AGHI MK, Nahed BV, Sloan AE, Ryken TC, et al
    The role of surgery in the management of patients with diffuse low grade glioma : A systematic review and evidence-based clinical practice guideline.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  351. NAHED BV, Redjal N, Brat DJ, Chi AS, et al
    Management of patients with recurrence of diffuse low grade glioma : A systematic review and evidence-based clinical practice guideline.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  352. CAHILL DP, Sloan AE, Nahed BV, Aldape KD, et al
    The role of neuropathology in the management of patients with diffuse low grade glioma : A systematic review and evidence-based clinical practice guideline.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  353. FOUKE SJ, Benzinger T, Gibson D, Ryken TC, et al
    The role of imaging in the management of adults with diffuse low grade glioma : A systematic review and evidence-based clinical practice guideline.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  354. ZIU M, Kalkanis SN, Gilbert M, Ryken TC, et al
    The role of initial chemotherapy for the treatment of adults with diffuse low grade glioma : A systematic review and evidence-based clinical practice guideline.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  355. SLOAN AE, Okada H, Ryken TC, Kalkanis SN, et al
    The role of emerging therapy in the management of patients with diffuse low grade glioma.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  356. RAGEL BT, Ryken TC, Kalkanis SN, Ziu M, et al
    The role of biopsy in the management of patients with presumed diffuse low grade glioma : A systematic review and evidence-based clinical practice guideline.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  357. XU G, Li JY
    ATP5A1 and ATP5B are highly expressed in glioblastoma tumor cells and endothelial cells of microvascular proliferation.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


    October 2015
  358. SHIN SM, Cooper BT, Chachoua A, Butler J, et al
    Survival but not brain metastasis response relates to lung cancer mutation status after radiosurgery.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  359. JENKINS NC, Rao G, Eberhart CG, Pedone CA, et al
    Somatic cell transfer of c-Myc and Bcl-2 induces large-cell anaplastic medulloblastomas in mice.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  360. MORFOUACE M, Nimmervoll B, Boulos N, Patel YT, et al
    Preclinical studies of 5-fluoro-2'-deoxycytidine and tetrahydrouridine in pediatric brain tumors.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  361. DEIKE K, Wiestler B, Graf M, Reimer C, et al
    Prognostic value of combined visualization of MR diffusion and perfusion maps in glioblastoma.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  362. TICHY J, Spechtmeyer S, Mittelbronn M, Hattingen E, et al
    Prospective evaluation of serum glial fibrillary acidic protein (GFAP) as a diagnostic marker for glioblastoma.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  363. ZHANG H, Liu Y, Zhou K, Zhou C, et al
    Genetic variations in the homologous recombination repair pathway genes modify risk of glioma.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  364. BOSNYAK E, Kamson DO, Robinette NL, Barger GR, et al
    Tryptophan PET predicts spatial and temporal patterns of post-treatment glioblastoma progression detected by contrast-enhanced MRI.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  365. EZZAT S, Kamal M, El-Khateeb N, El-Beltagy M, et al
    Pediatric brain tumors in a low/middle income country: does it differ from that in developed world?
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  366. FRENARD C, Peuvrel L, Jean MS, Brocard A, et al
    Development of brain metastases in patients with metastatic melanoma while receiving ipilimumab.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  367. CAINE C, Deshmukh S, Gondi V, Mehta M, et al
    CogState computerized memory tests in patients with brain metastases: secondary endpoint results of NRG Oncology RTOG 0933.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  368. FRANCESCHI S, Tomei S, Mazzanti CM, Lessi F, et al
    Association between RAD 51 rs1801320 and susceptibility to glioblastoma.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  369. SUBASHI E, Cordero FJ, Halvorson KG, Qi Y, et al
    Tumor location, but not H3.3K27M, significantly influences the blood-brain-barrier permeability in a genetic mouse model of pediatric high-grade glioma.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  370. OKSUZ E, Atalar F, Tanirverdi G, Bilir A, et al
    Therapeutic potential of cyclooxygenase-3 inhibitors in the management of glioblastoma.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  371. ROBINS HI, Zhang P, Gilbert MR, Chakravarti A, et al
    A randomized phase I/II study of ABT-888 in combination with temozolomide in recurrent temozolomide resistant glioblastoma: an NRG oncology RTOG group study.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  372. NAEHRIG DN, Koh ES, Vogiatzis M, Yanagisawa W, et al
    Impact of cognitive function on communication in patients with primary or secondary brain tumours.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  373. SHERMAN JC, Colvin MK, Mancuso SM, Batchelor TT, et al
    Neurocognitive effects of proton radiation therapy in adults with low-grade glioma.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  374. QAZI MA, Vora P, Venugopal C, McFarlane N, et al
    A novel stem cell culture model of recurrent glioblastoma.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  375. CHOY W, Ampie L, Lamano JB, Kesavabhotla K, et al
    Erratum to: Predictors of recurrence in the management of chordoid meningioma.
    J Neurooncol. 2015.
    PubMed     Text format    


  376. QI ZX, Cai JJ, Chen LC, Yue Q, et al
    TRIM28 as an independent prognostic marker plays critical roles in glioma progression.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  377. RICHTER A, Jenewein J, Krayenbuhl N, Woernle C, et al
    Are preoperative sex-related differences of affective symptoms in primary brain tumor patients associated with postoperative histopathological grading?
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  378. COHEN-INBAR O, Melmer P, Lee CC, Xu Z, et al
    Leukoencephalopathy in long term brain metastases survivors treated with radiosurgery.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  379. CUCCARINI V, Erbetta A, Farinotti M, Cuppini L, et al
    Advanced MRI may complement histological diagnosis of lower grade gliomas and help in predicting survival.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  380. HUNDSBERGER T, Hottinger AF, Roelcke U, Roth P, et al
    Patterns of care in recurrent glioblastoma in Switzerland: a multicentre national approach based on diagnostic nodes.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  381. KHAN OH, Mason W, Kongkham PN, Bernstein M, et al
    Neurosurgical management of adult diffuse low grade gliomas in Canada: a multi-center survey.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


    September 2015
  382. LOMBARDI G, Pace A, Pasqualetti F, Rizzato S, et al
    Predictors of survival and effect of short (40 Gy) or standard-course (60 Gy) irradiation plus concomitant temozolomide in elderly patients with glioblastoma: a multicenter retrospective study of AINO (Italian Association of Neuro-Oncology).
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  383. YEUNG TP, Wang Y, He W, Urbini B, et al
    Erratum to: Survival prediction in high-grade gliomas using CT perfusion imaging.
    J Neurooncol. 2015.
    PubMed     Text format    


  384. EDELSTEIN K, Coate L, Massey C, Jewitt NC, et al
    Illness intrusiveness and subjective well-being in patients with glioblastoma.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  385. CHOY W, Ampie L, Lamano JB, Kesavabhotla K, et al
    Predictors of recurrence in the management of chordoid meningioma.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  386. AREEB Z, Stylli SS, Koldej R, Ritchie DS, et al
    MicroRNA as potential biomarkers in Glioblastoma.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  387. ZHANG Y, Du Z, Zhuang Z, Wang Y, et al
    E804 induces growth arrest, differentiation and apoptosis of glioblastoma cells by blocking Stat3 signaling.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  388. OHUE S, Kohno S, Inoue A, Yamashita D, et al
    Evaluation of serial changes on computed tomography and magnetic resonance imaging after implantation of carmustine wafers in patients with malignant gliomas for differential diagnosis of tumor recurrence.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  389. DANKBAAR JW, Snijders TJ, Robe PA, Seute T, et al
    The use of F-FDG PET to differentiate progressive disease from treatment induced necrosis in high grade glioma.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  390. DASGUPTA T, Olow AK, Yang X, Hashizume R, et al
    Survival advantage combining a BRAF inhibitor and radiation in BRAF V600E-mutant glioma.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  391. ZHANG R, Han J, Daniels D, Huang H, et al
    Detecting the H3F3A mutant allele found in high-grade pediatric glioma by real-time PCR.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  392. MICKEVICIUS NJ, Carle AB, Bluemel T, Santarriaga S, et al
    Location of brain tumor intersecting white matter tracts predicts patient prognosis.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  393. CHO KR, Lee MH, Kong DS, Seol HJ, et al
    Outcome of gamma knife radiosurgery for metastatic brain tumors derived from non-small cell lung cancer.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  394. MINNITI G, Scaringi C, Paolini S, Clarke E, et al
    Repeated stereotactic radiosurgery for patients with progressive brain metastases.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  395. OZYURT J, Muller HL, Thiel CM
    A systematic review of cognitive performance in patients with childhood craniopharyngioma.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  396. MASCHIO M, Dinapoli L, Fabi A, Giannarelli D, et al
    Cognitive rehabilitation training in patients with brain tumor-related epilepsy and cognitive deficits: a pilot study.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  397. KAST R, Auner G, Yurgelevic S, Broadbent B, et al
    Identification of regions of normal grey matter and white matter from pathologic glioblastoma and necrosis in frozen sections using Raman imaging.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  398. BATES JE, Youn P, Usuki KY, Walter KA, et al
    Brain metastasis from melanoma: the prognostic value of varying sites of extracranial disease.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  399. PARK Y, Kim KS, Kim K, Chie EK, et al
    Nomogram prediction of survival in patients with brain metastases from hepatocellular carcinoma treated with whole-brain radiotherapy: a multicenter retrospective study.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  400. TAN LA, Kasliwal MK, Wewel J, Harbhajanka A, et al
    Neurosarcoidosis mimicking bilateral posterior fossa tentorial meningiomas.
    J Neurooncol. 2015.
    PubMed     Text format    


  401. WAKEFIELD A, Pignata A, Ghazi A, Ashoori A, et al
    Is CMV a target in pediatric glioblastoma? Expression of CMV proteins, pp65 and IE1-72 and CMV nucleic acids in a cohort of pediatric glioblastoma patients.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  402. LIU X, Lu D, Ma P, Liu H, et al
    Hugl-1 inhibits glioma cell growth in intracranial model.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  403. ZHANG XQ, Kiang KM, Wang YC, Pu JK, et al
    IDH1 mutation-associated long non-coding RNA expression profile changes in glioma.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  404. WEI W, Chen X, Ma X, Wang D, et al
    The efficacy and safety of various dose-dense regimens of temozolomide for recurrent high-grade glioma: a systematic review with meta-analysis.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  405. WANG X, Chen Y, Zhang S, Zhang L, et al
    Co-expression of COX-2 and 5-LO in primary glioblastoma is associated with poor prognosis.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  406. MUQUIT S, Parks R, Basu S
    Socio-economic characteristics of patients with glioblastoma multiforme.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  407. SIMON OJ, Muntefering T, Grauer OM, Meuth SG, et al
    The role of ion channels in malignant brain tumors.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  408. SHEEHAN JP, Cohen-Inbar O, Ruangkanchanasetr R, Bulent Omay S, et al
    Post-radiosurgical edema associated with parasagittal and parafalcine meningiomas: a multicenter study.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


    August 2015
  409. NAIR SK, Driscoll T, Boczkowski D, Schmittling R, et al
    Ex vivo generation of dendritic cells from cryopreserved, post-induction chemotherapy, mobilized leukapheresis from pediatric patients with medulloblastoma.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  410. KOHUTEK ZA, Yamada Y, Chan TA, Brennan CW, et al
    Long-term risk of radionecrosis and imaging changes after stereotactic radiosurgery for brain metastases.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  411. LADHA H, Pawar T, Gilbert MR, Mandel J, et al
    Wound healing complications in brain tumor patients on Bevacizumab.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  412. YU MO, Park KJ, Park DH, Chung YG, et al
    Reactive oxygen species production has a critical role in hypoxia-induced Stat3 activation and angiogenesis in human glioblastoma.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  413. DAHLIN AM, Hollegaard MV, Wibom C, Andersson U, et al
    CCND2, CTNNB1, DDX3X, GLI2, SMARCA4, MYC, MYCN, PTCH1, TP53, and MLL2 gene variants and risk of childhood medulloblastoma.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  414. ODIA Y, Kreisl TN, Aregawi D, Innis EK, et al
    A phase II trial of tamoxifen and bortezomib in patients with recurrent malignant gliomas.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  415. KOVACS A, Emri M, Opposits G, Pisak T, et al
    Changes in functional MRI signals after 3D based radiotherapy of glioblastoma multiforme.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  416. BLAKELEY JO, Grossman SA, Mikkelsen T, Rosenfeld MR, et al
    Phase I study of iniparib concurrent with monthly or continuous temozolomide dosing schedules in patients with newly diagnosed malignant gliomas.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  417. THOMAS AA, Arevalo-Perez J, Kaley T, Lyo J, et al
    Dynamic contrast enhanced T1 MRI perfusion differentiates pseudoprogression from recurrent glioblastoma.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  418. ZHONG X, Huang B, Feng J, Yang W, et al
    Delayed leukoencephalopathy of non-small cell lung cancer patients with brain metastases underwent whole brain radiation therapy.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  419. CHEN W, Zhang B, Guo W, Gao L, et al
    miR-429 inhibits glioma invasion through BMK1 suppression.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  420. MURATA H, Yoshimoto K, Hatae R, Akagi Y, et al
    Detection of proneural/mesenchymal marker expression in glioblastoma: temporospatial dynamics and association with chromatin-modifying gene expression.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  421. KAMIYA-MATSUOKA C, Cachia D, Yust-Katz S, Rodriguez YA, et al
    Ischemic stroke in patients with gliomas at The University of Texas-M.D. Anderson Cancer Center.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  422. SANDBERG DI, Rytting M, Zaky W, Kerr M, et al
    Methotrexate administration directly into the fourth ventricle in children with malignant fourth ventricular brain tumors: a pilot clinical trial.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  423. ABOU AL-SHAAR H, Almefty KK, Abolfotoh M, Arvold ND, et al
    Brachytherapy in the treatment of recurrent aggressive falcine meningiomas.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  424. AHLUWALIA MS, Chao ST, Parsons MW, Suh JH, et al
    Phase II trial of sunitinib as adjuvant therapy after stereotactic radiosurgery in patients with 1-3 newly diagnosed brain metastases.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  425. FANG KM, Liu JJ, Li CC, Cheng CC, et al
    Colchicine derivative as a potential anti-glioma compound.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  426. MEHTA AI, Linninger A, Lesniak MS, Engelhard HH, et al
    Current status of intratumoral therapy for glioblastoma.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  427. YAEH A, Nanda T, Jani A, Rozenblat T, et al
    Control of brain metastases from radioresistant tumors treated by stereotactic radiosurgery.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


    July 2015
  428. ALENTORN A, Duran-Pena A, Malousi A, Marie Y, et al
    Differential gene methylation in paired glioblastomas suggests a role of immune response pathways in tumor progression.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  429. JEIBMANN A, Halama K, Witte HT, Kim SN, et al
    Involvement of CD9 and PDGFR in migration is evolutionarily conserved from Drosophila glia to human glioma.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  430. JIAO JT, Sun J, Ma JF, Dai MC, et al
    Relationship between inflammatory cytokines and risk of depression, and effect of depression on the prognosis of high grade glioma patients.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  431. KEN S, Deviers A, Filleron T, Catalaa I, et al
    Voxel-based evidence of perfusion normalization in glioblastoma patients included in a phase I-II trial of radiotherapy/tipifarnib combination.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  432. HOLMES JA, Paulsson AK, Page BR, Miller LD, et al
    Genomic predictors of patterns of progression in glioblastoma and possible influences on radiation field design.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  433. TRIFILETTI DM, Patel N, Lee CC, Romano AM, et al
    Stereotactic radiosurgery in the treatment of brain metastases from gastrointestinal primaries.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


    June 2015
  434. SEE AP, Parker JJ, Waziri A
    The role of regulatory T cells and microglia in glioblastoma-associated immunosuppression.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  435. SCHNOOR R, Maas SL, Broekman ML
    Heparin in malignant glioma: review of preclinical studies and clinical results.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  436. PHILLIPS RE, Curran KJ, Khakoo Y
    Management of late extraneural recurrence of medulloblastoma without high-dose chemotherapy.
    J Neurooncol. 2015.
    PubMed     Text format    


  437. LIM M, Liau LM
    Introduction: brain tumor immunotherapy.
    J Neurooncol. 2015.
    PubMed     Text format    


  438. LIU Y, Alexander BM, Chen YH, Horvath MC, et al
    Salvage whole brain radiotherapy or stereotactic radiosurgery after initial stereotactic radiosurgery for 1-4 brain metastases.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  439. GRUSLOVA A, Cavazos DA, Miller JR, Breitbart E, et al
    VB-111: a novel anti-vascular therapeutic for glioblastoma multiforme.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  440. OLSON JJ, Kalkanis SN, Ryken TC
    Evidence-based clinical practice parameter guidelines for the treatment of adults with diffuse low grade glioma: introduction and methods.
    J Neurooncol. 2015.
    PubMed     Text format    


  441. JOSHI S, Ellis JA, Ornstein E, Bruce JN, et al
    Intraarterial drug delivery for glioblastoma mutiforme : Will the phoenix rise again?
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  442. STREIFF MB, Ye X, Kickler TS, Desideri S, et al
    A prospective multicenter study of venous thromboembolism in patients with newly-diagnosed high-grade glioma: hazard rate and risk factors.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  443. TRIFILETTI DM, Romano KD, Xu Z, Reardon KA, et al
    Leptomeningeal disease following stereotactic radiosurgery for brain metastases from breast cancer.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  444. AMPIE L, Choy W, Lamano JB, Fakurnejad S, et al
    Heat shock protein vaccines against glioblastoma: from bench to bedside.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  445. SHI H, Gong H, Cao K, Zou S, et al
    Nrdp1-mediated ErbB3 degradation inhibits glioma cell migration and invasion by reducing cytoplasmic localization of p27.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  446. AIZER AA, Du R, Wen PY, Arvold ND, et al
    Radiotherapy and death from cerebrovascular disease in patients with primary brain tumors.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  447. MULLER K, Henke G, Pietschmann S, van Gool S, et al
    Re-irradiation or re-operation followed by dendritic cell vaccination? Comparison of two different salvage strategies for relapsed high-grade gliomas by means of a new prognostic model.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  448. CAMPIAN JL, Ye X, Gladstone DE, Ambady P, et al
    Pre-radiation lymphocyte harvesting and post-radiation reinfusion in patients with newly diagnosed high grade gliomas.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  449. UNG N, Yang I
    Nanotechnology to augment immunotherapy for the treatment of glioblastoma multiforme.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  450. PATEL MA, Pardoll DM
    Concepts of immunotherapy for glioma.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  451. LI B, Sun SZ, Yang M, Shi JL, et al
    The correlation between EGFR mutation status and the risk of brain metastasis in patients with lung adenocarcinoma.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  452. AZAD TD, Razavi SM, Jin B, Lee K, et al
    Glioblastoma antigen discovery-foundations for immunotherapy.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  453. WELZEL G, Gehweiler J, Brehmer S, Appelt JU, et al
    Metronomic chemotherapy with daily low-dose temozolomide and celecoxib in elderly patients with newly diagnosed glioblastoma multiforme: a retrospective analysis.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  454. NAVARRIA P, Pessina F, Cozzi L, Clerici E, et al
    Hypofractionated stereotactic radiation therapy in skull base meningiomas.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  455. ANTONIOS JP, Everson RG, Liau LM
    Dendritic cell immunotherapy for brain tumors.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  456. KIVINIEMI A, Gardberg M, Frantzen J, Parkkola R, et al
    Serum levels of GFAP and EGFR in primary and recurrent high-grade gliomas: correlation to tumor volume, molecular markers, and progression-free survival.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  457. CHEN KT, Wu TW, Chuang CC, Hsu YH, et al
    Corpus callosum involvement and postoperative outcomes of patients with gliomas.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  458. RAHMAN R, Catalano PJ, Reardon DA, Norden AD, et al
    Incidence, risk factors, and reasons for hospitalization among glioblastoma patients receiving chemoradiation.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  459. KRAMER K, Pandit-Taskar N, Zanzonico P, Wolden SL, et al
    Low incidence of radionecrosis in children treated with conventional radiation therapy and intrathecal radioimmunotherapy.
    J Neurooncol. 2015;123:245-9.
    PubMed     Text format     Abstract available


  460. HIRONO S, Iwadate Y, Higuchi Y, Serizawa T, et al
    Stereotactic radiosurgery in combination with up-front high-dose methotrexate as a first-line treatment for newly diagnosed primary central nervous system lymphoma.
    J Neurooncol. 2015;123:237-44.
    PubMed     Text format     Abstract available


  461. GOLD CA, Lassman AB, Odia Y
    Opsoclonus-myoclonus syndrome in a patient with an anaplastic oligoastrocytoma.
    J Neurooncol. 2015;123:315-6.
    PubMed     Text format    


    May 2015
  462. ZHANG N, Ouyang T, Kang H, Long W, et al
    Adult medulloblastoma: clinical characters, prognostic factors, outcomes and patterns of relapse.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  463. PIIL K, Jakobsen J, Christensen KB, Juhler M, et al
    Health-related quality of life in patients with high-grade gliomas: a quantitative longitudinal study.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  464. KIM BS, Kim SK, Choi SH, Lee SH, et al
    Prognostic implication of progression pattern after anti-VEGF bevacizumab treatment for recurrent malignant gliomas.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  465. JOHNSTON DL, Keene D, Kostova M, Lafay-Cousin L, et al
    Survival of children with medulloblastoma in Canada diagnosed between 1990 and 2009 inclusive.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  466. PALMER JD, Siglin J, Yamoah K, Dan T, et al
    Re-resection for recurrent high-grade glioma in the setting of re-irradiation: more is not always better.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  467. FAY M, Head R, Martin J
    Where is the radiobiology and pharmacology research to improve outcomes in glioblastoma?
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  468. WANG D, Hu E, Wu P, Yuan W, et al
    Genetic variant near TERC influencing the risk of gliomas with older age at diagnosis in a Chinese population.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  469. TIEU MT, Lovblom LE, McNamara MG, Mason W, et al
    Impact of glycemia on survival of glioblastoma patients treated with radiation and temozolomide.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  470. GRAILLON T, Defilles C, Mohamed A, Lisbonis C, et al
    Combined treatment by octreotide and everolimus: Octreotide enhances inhibitory effect of everolimus in aggressive meningiomas.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  471. HAN S, Li X, Qiu B, Jiang T, et al
    Can lateral ventricle contact predict the ontogeny and prognosis of glioblastoma?
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  472. SASAKI H, Hirose Y, Yazaki T, Kitamura Y, et al
    Upfront chemotherapy and subsequent resection for molecularly defined gliomas.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  473. YUST-KATZ S, Mandel JJ, Wu J, Yuan Y, et al
    Venous thromboembolism (VTE) and glioblastoma.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  474. BOURAS A, Kaluzova M, Hadjipanayis CG
    Radiosensitivity enhancement of radioresistant glioblastoma by epidermal growth factor receptor antibody-conjugated iron-oxide nanoparticles.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  475. WANG Y, Liu S, Fan X, Li S, et al
    Age-associated brain regions in gliomas: a volumetric analysis.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  476. DOS SANTOS MA, Pignon JP, Blanchard P, Lefeuvre D, et al
    Systematic review and meta-analysis of phase I/II targeted therapy combined with radiotherapy in patients with glioblastoma multiforme: quality of report, toxicity, and survival.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  477. JOHNSTON DL, Keene D, Bartels U, Carret AS, et al
    Low grade astrocytoma in children under the age of three years: a report from the Canadian pediatric brain tumour consortium.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  478. WANG FR, Jiang YS
    Effect of treatment with baicalein on the intracerebral tumor growth and survival of orthotopic glioma models.
    J Neurooncol. 2015.
    PubMed     Text format     Abstract available


  479. YANG C, Li G, Fang J, Wu L, et al
    Clinical characteristics and surgical outcomes of primary spinal paragangliomas.
    J Neurooncol. 2015;122:539-47.
    PubMed     Text format     Abstract available


  480. BOURDILLON P, Hlaihel C, Guyotat J, Guillotton L, et al
    Prediction of anaplastic transformation in low-grade oligodendrogliomas based on magnetic resonance spectroscopy and 1p/19q codeletion status.
    J Neurooncol. 2015;122:529-37.
    PubMed     Text format     Abstract available


  481. ERDEM-ERASLAN L, Heijsman D, de Wit M, Kremer A, et al
    Tumor-specific mutations in low-frequency genes affect their functional properties.
    J Neurooncol. 2015;122:461-70.
    PubMed     Text format     Abstract available


  482. MURPHY ES, Xie H, Merchant TE, Yu JS, et al
    Review of cranial radiotherapy-induced vasculopathy.
    J Neurooncol. 2015;122:421-9.
    PubMed     Text format     Abstract available


  483. IOANNIDIS P, Mamouli D, Foroglou N
    Expanding schwannomatosis phenotype.
    J Neurooncol. 2015;122:607-9.
    PubMed     Text format    


    April 2015
  484. GOLDWIRT L, Beccaria K, Carpentier A, Idbaih A, et al
    Preclinical impact of bevacizumab on brain and tumor distribution of irinotecan and temozolomide.
    J Neurooncol. 2015;122:273-81.
    PubMed     Text format     Abstract available


  485. SI MY, Fan ZC, Li YZ, Chang XL, et al
    The prognostic significance of serum and cerebrospinal fluid MMP-9, CCL2 and sVCAM-1 in leukemia CNS metastasis.
    J Neurooncol. 2015;122:229-44.
    PubMed     Text format     Abstract available


  486. TAN LA, Kasliwal MK, Arvanitis LD, Byrne RW, et al
    Enlarging scalp mass.
    J Neurooncol. 2015;122:419-20.
    PubMed     Text format    


  487. CHAMBERLAIN MC
    Salvage therapy with lomustine for temozolomide refractory recurrent anaplastic astrocytoma: a retrospective study.
    J Neurooncol. 2015;122:329-38.
    PubMed     Text format     Abstract available


  488. MCLENDON RE, Lipp E, Satterfield D, Ehinger M, et al
    Prognostic marker analysis in pediatric intracranial ependymomas.
    J Neurooncol. 2015;122:255-61.
    PubMed     Text format     Abstract available


  489. SAKATA A, Okada T, Yamamoto A, Kanagaki M, et al
    Grading glial tumors with amide proton transfer MR imaging: different analytical approaches.
    J Neurooncol. 2015;122:339-48.
    PubMed     Text format     Abstract available


    March 2015
  490. KAZDA T, Hardie JG, Pafundi DH, Kaufmann TJ, et al
    Evaluation of RANO response criteria compared to clinician evaluation in WHO grade III anaplastic astrocytoma: implications for clinical trial reporting and patterns of failure.
    J Neurooncol. 2015;122:197-203.
    PubMed     Text format     Abstract available


  491. PARK ER, Smith KB, Merker VL, Muzikansky A, et al
    Examining perceived cancer risk among patients with neurofibromatosis type 1.
    J Neurooncol. 2015;122:127-33.
    PubMed     Text format     Abstract available


  492. CECCATO F, Lombardi G, Manara R, Emanuelli E, et al
    Temozolomide and pasireotide treatment for aggressive pituitary adenoma: expertise at a tertiary care center.
    J Neurooncol. 2015;122:189-96.
    PubMed     Text format     Abstract available


  493. AHLUWALIA MS, Xie H, Dahiya S, Hashemi-Sadraei N, et al
    Efficacy and patient-reported outcomes with dose-intense temozolomide in patients with newly diagnosed pure and mixed anaplastic oligodendroglioma: a phase II multicenter study.
    J Neurooncol. 2015;122:111-9.
    PubMed     Text format     Abstract available


  494. WANG R, Chen W, Zhang Q, Liu Y, et al
    Phosphodiesterase type 5 inhibitor Tadalafil increases Rituximab treatment efficacy in a mouse brain lymphoma model.
    J Neurooncol. 2015;122:35-42.
    PubMed     Text format     Abstract available


  495. AHMED KA, Freilich JM, Sloot S, Figura N, et al
    LINAC-based stereotactic radiosurgery to the brain with concurrent vemurafenib for melanoma metastases.
    J Neurooncol. 2015;122:121-6.
    PubMed     Text format     Abstract available


    February 2015
  496. WANG Y, Fan X, Zhang W, Zhang C, et al
    Deficiency of very large G-protein-coupled receptor-1 is a risk factor of tumor-related epilepsy: a whole transcriptome sequencing analysis.
    J Neurooncol. 2015;121:609-16.
    PubMed     Text format     Abstract available


  497. OGIWARA H, Tsutsumi Y, Matsuoka K, Kiyotani C, et al
    Apparent diffusion coefficient of intracranial germ cell tumors.
    J Neurooncol. 2015;121:565-71.
    PubMed     Text format     Abstract available


  498. MULDOON LL, Wu YJ, Pagel MA, Neuwelt EA, et al
    N-acetylcysteine chemoprotection without decreased cisplatin antitumor efficacy in pediatric tumor models.
    J Neurooncol. 2015;121:433-40.
    PubMed     Text format     Abstract available


  499. STROHBEHN G, Coman D, Han L, Ragheb RR, et al
    Imaging the delivery of brain-penetrating PLGA nanoparticles in the brain using magnetic resonance.
    J Neurooncol. 2015;121:441-9.
    PubMed     Text format     Abstract available


  500. ESEN H, Erdi F, Kaya B, Feyzioglu B, et al
    Tissue thioredoxin reductase-1 expression in astrocytomas of different grades.
    J Neurooncol. 2015;121:451-8.
    PubMed     Text format     Abstract available


  501. YU T, Kang HC, Lim do H, Kim IH, et al
    Pattern of care of anaplastic oligodendroglioma and oligoastrocytoma in a Korean population: the Korean Radiation Oncology Group study 13-12.
    J Neurooncol. 2015;121:531-9.
    PubMed     Text format     Abstract available


  502. XIONG Z, Zhang J, Li Z, Jiang J, et al
    A comparative study of intraventricular central neurocytomas and extraventricular neurocytomas.
    J Neurooncol. 2015;121:521-9.
    PubMed     Text format     Abstract available


  503. WU L, Yang T, Deng X, Yang C, et al
    Treatment strategies and long-term outcomes for primary intramedullary spinal germinomas: an institutional experience.
    J Neurooncol. 2015;121:541-8.
    PubMed     Text format     Abstract available


    January 2015
  504. PACKER RJ, Rood BR, Turner DC, Stewart CF, et al
    Phase I and pharmacokinetic trial of PTC299 in pediatric patients with refractory or recurrent central nervous system tumors: a PBTC study.
    J Neurooncol. 2015;121:217-24.
    PubMed     Text format     Abstract available


  505. GURSEL DB, Banu MA, Berry N, Marongiu R, et al
    Tight regulation between cell survival and programmed cell death in GBM stem-like cells by EGFR/GSK3b/PP2A signaling.
    J Neurooncol. 2015;121:19-29.
    PubMed     Text format     Abstract available


  506. BEN ABDELWAHED BAGGA R, Donnou S, Cosette J, Sautes-Fridman C, et al
    Mouse models of primary central nervous system lymphomas: tools for basing funding and therapeutic strategies.
    J Neurooncol. 2015;121:9-18.
    PubMed     Text format     Abstract available


  507. DUDLEY RW, Torok MR, Gallegos D, Liu AK, et al
    Pediatric choroid plexus tumors: epidemiology, treatments, and outcome analysis on 202 children from the SEER database.
    J Neurooncol. 2015;121:201-7.
    PubMed     Text format     Abstract available


  508. CANNON DM, Mohindra P, Gondi V, Kruser TJ, et al
    Choroid plexus tumor epidemiology and outcomes: implications for surgical and radiotherapeutic management.
    J Neurooncol. 2015;121:151-7.
    PubMed     Text format     Abstract available


  509. KILDAY JP, Laughlin S, Urbach S, Bouffet E, et al
    Diabetes insipidus in pediatric germinomas of the suprasellar region: characteristic features and significance of the pituitary bright spot.
    J Neurooncol. 2015;121:167-75.
    PubMed     Text format     Abstract available


  510. SASAGAWA Y, Akai T, Tachibana O, Iizuka H, et al
    Diagnostic value of interleukin-10 in cerebrospinal fluid for diffuse large B-cell lymphoma of the central nervous system.
    J Neurooncol. 2015;121:177-83.
    PubMed     Text format     Abstract available


  511. JENKINSON MD, Weber DC, Haylock BJ, Mallucci CL, et al
    Atypical meningoma: current management dilemmas and prospective clinical trials.
    J Neurooncol. 2015;121:1-7.
    PubMed     Text format     Abstract available


  512. AKHTER A, Masir N, Elyamany G, Phang KC, et al
    Differential expression of Toll-like receptor (TLR) and B cell receptor (BCR) signaling molecules in primary diffuse large B-cell lymphoma of the central nervous system.
    J Neurooncol. 2015;121:289-96.
    PubMed     Text format     Abstract available


  513. WEBER DC, Ares C, Malyapa R, Albertini F, et al
    Tumor control and QoL outcomes of very young children with atypical teratoid/rhabdoid tumor treated with focal only chemo-radiation therapy using pencil beam scanning proton therapy.
    J Neurooncol. 2015;121:389-97.
    PubMed     Text format     Abstract available


  514. WALBERT T, Mendoza TR, Vera-Bolanos E, Acquaye A, et al
    Symptoms and socio-economic impact of ependymoma on adult patients: results of the Adult Ependymoma Outcomes Project 2.
    J Neurooncol. 2015;121:341-8.
    PubMed     Text format     Abstract available


  515. TAAL W, van der Rijt CC, Dinjens WN, Sillevis Smitt PA, et al
    Treatment of large low-grade oligodendroglial tumors with upfront procarbazine, lomustine, and vincristine chemotherapy with long follow-up: a retrospective cohort study with growth kinetics.
    J Neurooncol. 2015;121:365-72.
    PubMed     Text format     Abstract available


    September 2014
  516. AHMETI H, Balschun K, Mehdorn HM, Stark AM, et al
    Unusual coincidence of a pituitary adenoma and an aspergilloma of the sphenoid sinus.
    J Neurooncol. 2014;119:447-8.
    PubMed     Text format    


  517. PUZIK A, Moske-Eick O, Kontny U
    A young boy with a paravertebral mass and symptoms of spinal compression.
    J Neurooncol. 2014;119:445-6.
    PubMed     Text format    


  518. SCOTT BJ, van Vugt VA, Rush T, Brown T, et al
    Concurrent intrathecal methotrexate and liposomal cytarabine for leptomeningeal metastasis from solid tumors: a retrospective cohort study.
    J Neurooncol. 2014;119:361-8.
    PubMed     Text format     Abstract available


  519. FENG J, Hong L, Wu Y, Li C, et al
    Identification of a subtype-specific ENC1 gene related to invasiveness in human pituitary null cell adenoma and oncocytomas.
    J Neurooncol. 2014;119:307-15.
    PubMed     Text format     Abstract available


  520. HAN YP, Ma CK, Wang SQ, Enomoto A, et al
    Evaluation of osteopontin as a potential biomarker for central nervous system embryonal tumors.
    J Neurooncol. 2014;119:343-51.
    PubMed     Text format     Abstract available


    May 2014
  521. SREDNI ST, Patel K, D'Almeida Costa F, de Fatima Bonaldo M, et al
    Activation of ErbB2- ErbB3 signaling pathway supports potential therapeutic activity of ErbB inhibitors in AT/RT.
    J Neurooncol. 2014;118:201-3.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Neoplasms of the CNS is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: